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Abstract 
 
Increasing evidence shows that cardiac nuclear imaging with use of SPECT, PET or hybrid 
imaging plays an important role in providing valuable information about myocardial viability, 
perfusion and function.  This study was conducted to investigate the diagnostic value of 
cardiac nuclear imaging techniques, cardiac SPECT and PET with regard to their clinical 
value in the diagnostic assessment of patients with suspected or known coronary artery 
disease. The research was performed in four stages, with stage 1 covering a comprehensive 
systematic literature review of diagnostic performance of SPECT, PET and SPECT/CT and 
PET/CT in the diagnosis of coronary artery disease; stage 2 is a retrospective analysis of head 
to head comparison of cardiac SPECT with coronary calcium scores in coronary artery 
disease; stage 3 is a phantom study with experiments conducted on an anthropomorphic 
cardiac phantom, while stage 4 involves a prospective study of comparing cardiac PET with 
SPECT, echocardiography and invasive angiography in terms of the diagnostic value in 
myocardial viability.  
A systematic literature review was first conducted with the aim of identifying the current 
research direction with regard to the diagnostic value of SPECT, PET and integrated PET/CT 
in coronary artery disease. Our analysis consisting of 25 studies shows that PET has high 
diagnostic value with mean sensitivity and specificity of 91% and 89% in diagnosing 
coronary artery disease, when compared with SPECT or integrated SPECT/CT imaging 
modality. 
 
Coronary artery calcium (CAC) score has been regarded as a reliable marker to predict future 
cardiac events. However, the extent to which the added value of CAC score to the diagnostic 
performance of myocardial perfusion imaging (MPI) by SPECT remains unclear. In this stage 
of the study, a retrospective review of the CAC scores and cardiac SPECT was conducted in 
48 patients with suspected coronary artery disease. Results showed that there is a lack of 
correlation between the CAC scores and MPI-SPECT assessments with a significant 
difference observed between these two techniques, especially in patients with zero or mild 
calcification (CAC scores 0-100).  Of 48% of the patients with CAC scores more than 100, 
only 44% of these patients demonstrated abnormal, or probably abnormal SPECT imaging.  
Of the 25% of patients with a zero CAC score, only 6% had normal MPI-SPECT findings.  
12 
 
This study further highlights the suggestion that CAC score should be combined with 
myocardial perfusion imaging in low-to-intermediate risk patients to improve the diagnostic 
performance. 
 
In the phantom experiments, we have developed a thorax-heart phantom with insertion of 
infarcted areas in the left ventricular wall, and tested SPECT myocardial perfusion imaging. 
Both normal myocardium and simulated abnormal areas are clearly visualized on SPECT 
images. The phantom can be used for further studies; in particular, optimization of nuclear 
cardiac imaging protocols for radiation dose reduction. 
 
The last part of this research project is a prospective multi-centre study involving recruitment 
of 30 patients with known or proven coronary artery disease.  Although only 10 patients met 
our strict selection criteria, all of these patients underwent 
18
F-FDG PET, 
99m
Tc-tetrofosmin 
SPECT, echocardiography and invasive coronary angiography. This study concludes that 
18
FDG PET has the highest diagnostic value in the assessment of myocardial viability, with 
100% sensitivity compared to other imaging modalities. 
18
F-FDG PET is superior to SPECT 
in the accurate assessment of myocardial changes, with excellent inter-observer agreement. 
In summary, the results of this project show that 
18
F-FDG PET has high diagnostic value for 
diagnosing coronary artery disease. Furthermore, FDG-PET is a valuable technique for 
assessment of myocardial viability when compared to other functional imaging modalities 
such as SPECT and echocardiography.  More prospective studies based on a large cohort are 
needed to confirm the diagnostic performance of cardiac PET in coronary artery disease, 
especially in guiding patient management. 
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Chapter 1  Introduction and literature review 
 
1.1 Coronary artery 
1.1.1 Normal anatomy 
 
Coronary artery system consists of left and right coronary arteries arising from ostia in the 
left and right sinuses of Valsalva.
1,2
 Left main coronary artery (LM) gives rise to the left 
anterior descending coronary artery (LAD) and left circumflex coronary artery (LCX). The 
LAD courses in the anterior epicardial ventricular septum and is further divided into 
proximal, mild, and distal segments. The LCX runs in the left atrial ventricular sulcus and 
gives rise to obtuse marginal branches (OM).  The length of left main coronary artery varies 
from 1 to 2.5 cm before bifurcating into the LAD and LCX branches. The length of LAD is 
around 10-13 cm. Usually,  length of LCX ranges from 6-8 cm and the right coronary artery 
is about 12-14 cm in length before giving arise to the posterior descending artery.
3,4
 
The right artery (RCA) originates from right coronary sinus and is further divided into 
proximal, mild, and distal segments. The proximal segment of the RCA is form the ostuim to 
the origin of first acute marginal artery. The sinoatrial artery originates from the proximal 
RCA and is the second artery to be visualised. RCA is protected by fat and runs deep in the 
right arteriole-ventricular sulcus with the right atrium (RA) cephalad and the right ventricle 
(RV) caudad. It continues to pass around the AM of the heart and then posteriorly, remaining 
in the AV sulcus until reaches the inter-ventricular sulcus at the crux. It gives a number of 
branches during its course surrounding the myocardium.  
The posterior descending artery (PDA) originates from the RCA, LCX, or both dominances. 
Approximately 80% of humans are RCA dominance. In RCA dominance, the distal RCA at 
the level of crux of the heart typically bifurcates into the PDA and a posterior-lateral branch. 
The PDA courses in the posterior ventricular septum giving origin to the SA nodal artery and 
posterior ventricular branch while, in LCX dominance, the PDA originates from the distal 
LCX. In both dominances, there are right and left PDAs originating from the RCA and 
LCX.
5,6
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1.1.2 Coronary artery disease 
 
Coronary artery disease (CAD), also known as coronary heart disease (CHD), is a condition 
of the coronary arteries with supply of oxygen and nutrients to the heart muscle being 
interrupted. When the regional arteries are insufficient to carry the oxygen to the heart 
muscle, this may lead to cause of death as result of CAD. CAD is the leading cause of 
mortality and morbidity in developed countries, despite recent advances in diagnostic 
techniques and treatments. In 2008, one in six Australians had coronary artery disease and it 
is estimated to be 3.4 million people of the total population. One in three Australians die of 
CAD and estimated around 46,000 people from the total CAD patients.
7,8
 In America more 
than 16 million people have CAD and about 385,000 die every year from CAD.
9
 
Coronary artery wall is composed of three layers, namely intima, media and adventitia and 
the major element of the atherosclerotic plaque is deposition of plaque consisting of lipid, 
fibrous connective tissue and calcium in the artery wall.
10-12
 As the plaque accumulates in the 
coronary arteries, blood supply to the heart muscle is decreased which results in ischemia, a 
local and temporary impairment of circulatory and myocardial damage as an infarction (an 
area of ischemic necrosis). Atherosclerosis is an active, different stage of disease process 
which develops in the arterial wall. There are diverse factors contributing to the growth and 
advancement of atherosclerosis. The earliest sign of atherosclerosis is endothelium 
dysfunction causing change to the vascular homeostasis by regulating vascular tone, smooth 
muscle cell proliferation and thrombogenicity.
13
 
Thus, the change of homeostasis leads to destabilisation of vascular regulatory mechanisms 
and leads to destruction to the arterial wall. Furthermore, inflammation, macrophage 
infiltration, extracellular medium digestion, oxidative stress, lipid deposition, calcification, 
cell apoptosis and thrombosis are almost futures of molecular mechanisms giving to plaque 
growth and movement.
14 
The total direct and indirect cost of cardiovascular disease and 
stroke in the United States for 2010 is estimated to be $503.2 billion.  In comparison, in 2008, 
the estimated cost of all cancer and benign neoplasms was $228 billion.  Due to the current 
global focus on healthcare utilization, costs, and quality, it is essential to monitor and 
understand the magnitude of healthcare delivery and costs, as well as the quality of healthcare 
delivery in relation to the cardiovascular disease. There are several imaging modalities that 
can be used to detect the CAD with variable diagnostic value. 
15 
 
1.2 Imaging modalities in the diagnosis of coronary artery disease 
1.2.1  Invasive coronary angiography 
1.2.1.1 Imaging Principles 
 
The diagnostic evaluation of coronary artery disease is important for inspection of function, 
perfusion and viability of heart muscle in addition to the assessment of the morphology and 
function of the coronary arteries. Coronary angiography (CA) is currently regarded as the 
gold standard to determine the degree of stenosis in coronary artery disease.
15-18
 Coronary 
angiography is a safe invasive technique but it is associated with harmful risks.  Therefore, 
the need arises for exploring non-invasive techniques such as coronary computed 
tomography, echocardiography, cardiac magnetic resonance imaging and cardiac nuclear 
medicine imaging. 
CA offers the most consistent evidence responsible for applying treatment in patients with 
CAD. CA has been established as a routine procedure on a daily clinical practice. The 
necessity of clinical practice to do the invasive CA in catheterization laboratory involves 
radiographic system, equipment for physiologic data, nursing and acquisition console, and kit 
for emergency patients care. Modern x-ray imaging is essential for optimal visualisation of 
the coronary arteries. CA is performed under local anaesthesia with small diameter catheters 
inserted through a trans-arterial sheath.
19
 
Patients with suspected CAD who have severe symptoms and those with definited high risk 
for CAD should be recommended for CA.  Low ejection fraction and poor exercise volume 
on an exercise test are included in the high risk criteria. Acute coronary syndromes refer to 
unstable angina, myocardial infarction and high risk features for developing ongoing 
ischemia and heart failure.
20
 
 
1.2.1.2 Diagnostic accuracy 
 
CAD is defined as more than 50% angiographic diameter stenosis in one or more of the 
coronary arteries. CAD is classified as single, double or triple vessel disease. When stenosis 
is less than 50% it is reflected as non-symptom producing, excluding cases with active 
obstruction.  Recent studies have examined the case of acute coronary syndromes which 
16 
 
mostly commonly occur at the location of coronary stenosis with < 50% diameter stenosis, 
and it is probably associated with thin cap fibro-atheroma.
21,22
  Recording systems have been 
established to precisely characterise the coronary vasculature with regard to the amount of 
lesions and their functional influence, locality, and density.
23,24
 
According to a recent study for invasive coronary angiography accuracy of coronary in-stent 
restenosis illustration that sensitivity, specificity and positive predictive value, and negative 
were 92%, 81% and 98%.
25
 Moreover, another study demonstrated that invasive coronary 
angiography with <50% diameter stenosis had a sensitivity of 67%, specificity 75%, positive 
average likelihood ratio of 2.6 and negative average likelihood ratio of 0.4 predictive values. 
26
 
CA advances in the consideration of pathophysiology of atherosclerotic plaque validate that 
in encouraging stages of plaque development, the plaque is vulnerable to rapture.  Also, CA 
option is to use the diagnostic examination tool with other invasive devices with patient still 
in the characterisation workroom. Both anatomy and physiology of coronary arteries can be 
simply evaluated with these additional procedures.
 27,28
   
The choice of imaging method should be exclusive to all individuals on the medical decision 
of patient risk, clinical history, and local knowledge. CA will continue to be the technique of 
high-quality with great possibility for an invasive supportive procedure, particularly in acute 
coronary conditions.
 29
 
 
1.2.1.3  Limitations  
 
The major complications are infrequent occurrence during diagnostic procedures; vascular 
complications related to the arterial puncture site are the most common complication, allergic 
to contrast reactions, deteriorating kidney function, cerebrovascular accidents, iatrogenic 
coronary artery dissection are  potential life threatening and mortality risk is 0.1%.  Usually, 
CA is performed by emergent coronary artery stenting or bypass surgery.
 30
  
Coronary angiography is a safe invasive procedure, but it is still as associated with potential 
harmful risks. Therefore, the need arises for exploring non-invasive techniques as a substitute 
for the study of coronary artery.
 31-33
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Although, repetitive invasive coronary artery was linked with higher early mortality and the 
trend towards a mortality reduction at follow up. Future approaches should investigate 
methods to minimise the primary hazard and increase advanced benefits by concentrating on 
higher risk patients and improving effectiveness of intervention.
34
 
1.2.2 Echocardiography 
1.2.2.1 Imaging Principles 
 
Ultrasound waves are sound waves with higher than perceptible frequency. The perceptible 
frequency ranges from 20 hertz (Hz) to 20,000Hz (20 kHz). Ultrasound frequency range used 
in cardiac imaging applications of 1-10MHz (megahertz). The sound wave is longitudinal 
wave, consisting of cyclic pressure deviation with explorations counting movement of 
encountered media particles in trend of wave transmission. The imaging resolution is 
controlled by wavelength. 
35
 
The wavelength less than 1mm is obtained to get adequate resolution in echocardiography. 
The higher frequency corresponds to a shorter wavelength, and vice versa..  
Echocardiography imaging characterises the demonstration of incoming ultrasound waves 
from studied structures, with location determined by their travel time. The electrical signal 
with radiofrequency (RF) is generated by incoming echo.
35-37
 
Plus-Wave Doppler technology is used in colour flow Doppler but with the calculation of 
multiple regions of interest within the pathway of the sound beam.  A flow velocity 
approximation is covered on the two dimensional (2D) image with a colour scale created on 
flow course, mean velocity and occasionally velocity variance, in all of multiple regions.
38-40
 
The affected structure in this situation is tissue, such as myocardium, which has higher degree 
of backscatter ultrasound and an inferior velocity than the red blood cells. The three 
dimensional (3D) systems suggest the opportunity of quantifying distances and area straight 
in the images.
 41-44
   
The 3D echocardiography could demonstrate lesions such as an atrial septal defect very well. 
The precise location of the defect, its relation to adjacent valves, vena cava, and pulmonary 
veins, are also easily located. In addition, measurements of the size, length of pathological 
lesions, volume and function of cardiac chambers which may influence management 
decisions can be obtained. 
45-48
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The ability to reconstruct the chamber in all its dimensions and slice it three-dimensionally 
could aid in measuring left ventricular volume and ejection fraction accurately without any 
geometric assumptions. This could be especially helpful in ventricles with distorted shape.
48-
51 
 
1.2.2.2 Diagnostic accuracy 
 
A recent study indicated that, using the diastolic and systolic peak velocities DPV /SPV at 
rest after stress of  <0.6 cm/s had sensitivity of 83%, a specificity of 94% and an accuracy of 
92% for identifying abnormal segments.
52, 53
  On the other hand, all these three diagnostic 
performance values increased to 100% when using the diastolic and systolic peak velocities 
(DPV/SPV) at rest after stress of <1.5 cm/s. 
54
 
Assessment of the myocardial microcirculation by myocardial contrast echocardiography 
(MCE) is a perfect imaging tool. MCE notices contrast MB at the vessel level within the 
myocardium. Thus, it is possible to measure tissue viability.
 55
  
At baseline, about 8% of left ventricular mass is established by blood current in the 
microcirculation named myocardial blood volume (MBV), 90% of which is included of blood 
in the capillaries. In normally perfused myocardium, the rate of capillary blood flow is 1 
mm/s. Saturation of the coronary microvasculature by MB then incomes about 5 s. When 
there is no flow controlling stenosis, MBV increases 5 times during hyperemia (stress 
testing), and so the myocardium refills in 1s.
 55
 
While, these approaches enhanced the signal-to-noise ratio, off-line image processing is 
frequently required to evaluate myocardial perfusion, because tissue signals is still present. 
Harmonic imaging also used high acoustic powers that destroyed MB. Thus, the imaging 
surround rate had to be concentrated significantly with electrocardiographic starting to 
tolerate MB to replace the myocardial microcirculation between pulses.
 56-57
 
Also, it is not evaluated whether the echocardiogram created new, clinically unsuspected 
evidence or it just confirmed the results from clinical valuation. There is substantial 
consideration as to the quantity of training essential in order to achieve and understand 
echocardiograms in critically ill patients and a requirement of skills has been recommended.  
One of the recommendations is operators with exact training. They are able to achieve 
19 
 
concentrated echocardiography in the peri-resuscitation location to distinguish gross 
pathology such as a large pericardial effusion, severe left ventricular damage, right 
ventricular dilatation, and gross hypo-volaemia, trusting on two-dimensional imaging only.
58-
65
 
 
1.2.2.3 Limitations 
 
Several limitations exist in 3D echocardiography imaging. First, system sensitivity is still limited to 
some extent. The definition of the endocardia borders is a crucial issue in quantitative 
echocardiography, and the determination of right ventricular volume requires saline contrast 
enhancement to adequately locate right ventricular endocardium for the purpose of measurement. 
Second, the frame rate of echocardiography is 22 frames/seconds. This relatively slow frame rate may 
provide sufficient samples at slow heart rates but could be quite problematic for the determination of 
volumes in small children and infants or in adults with high heart rates.. Third, there is a lack of 
evidence supporting the overview of echocardiography for the intensive care units.
63
 When 
accurate RF function assessment is required, traditional echocardiography techniques are far 
from being perfect.
66,67 
 
1.2.3 Coronary magnetic resonance angiography 
1.2.3.1 Imaging Principles 
 
More than decades, magnetic resonance imaging (MRI) has been increasingly used for 
medical diagnosis and research determination. MRI is used to create anatomical images of 
soft tissue without exposing subjects to ionizing radiation. MRI can be obtained in any direction 
and plane, without any restriction to the angulation of the images. Cardiac MRI has experienced 
tremendous developments and its capability to cardiovascular MR (CMR) imaging which 
contains sequences capable of diagnosing cardiovascular disease, such as valuation of 
regional myocardial perfusion measurement in patients with heart diseases.
68
 
CMR has a very high sensitivity and specificity for detecting diseases of the thoracic aorta 
such as aneurysm, acute dissection and intramural haemorrhage. 
69
Typically, the perfusion 
defect is the outcome of severe coronary stenosis, while regional micro-vascular connection 
20 
 
in earlier infarcted segments can similarly principal to a perfusion defect, even in the lack of 
an epicedial coronary artery obstruction.  The occurrence of collateral circulation can 
decrease a perfusion defect, also in important coronary lesions.
70   
 
 
1.2.3.2 Diagnostic accuracy 
 
Cardiovascular MRI (CMR) involves advanced technology, with a high-field magnet such as 
1.5 Tesla, although 3.0 Tesla systems are now gradually used, fast switching gradient coils, 
and coils for transmission and signal response. In contrast to other imaging techniques, MRI 
has the exclusive capability of tissue description. 
Proton density, T1 and T2 relaxation times which can vary significantly for a dissimilar tissue 
is subjective image contrast.  Alternative to change image contrast is by controlling the way 
that radio-frequency pulses are played. MRI scan is free from radiation and ionizing 
exposure, and there are no damaging biological side effects of MRI providing that safety 
guidelines are monitored. 
71
 
Coronary MR Angiography of the right and left coronary artery systems were imaged using 
an earlier designated free-breathing electrocardiogram triggered 3D composed steady state 
free precession coronary magnetic resonance imaging sequence.
72
  The delayed enhancement 
imaging is the most established MRI technique for detecting infarcted myocardium.  
Current studies have concentrated on delayed enhancement in the acute phase, with emphasis 
on assessing peri-infarct border zone areas and myocardium at risk.
73,74  
Delayed 
enhancement magnetic resonance imaging (DE-MRI) precisely displays regional myocardial 
necrosis in ischaemic heart disease.
 75
  
Since of the high spatial resolution, DE-MRI has the capability to measure the myocardial 
infarct, which is important for distinguishing between viable and non-viable. Myocardium 
Presently DE-MRI is reflected to be the technique of choice for measuring myocardial infarct 
volume.
76
 
21 
 
Magnetic Resonance Angiography (MRA) perfusion imaging has a sensitivity of 87% and 
specificity of 85% in detecting more than 50% stenosis.
77,78    
MRA perfusion had a sensitivity 
of 93% and specificity of 75% in identifying 70% stenosis.
79
 
Also, MRI has sensitivity of 87%, specificity 77% and accuracy 83%. 
80   
Recent study 
indicates that 3-T perfusion CMR is superior to 1.5-T perfusion CMR in the diagnosis of 
important single-vessel and multi-vessel coronary disease.
 81
  
Usually, clinical situation, with more than 95% of the registered patients effectively finishing 
both MR studies, 3-T perfusion CMR had high sensitivity of 98% and negative predictive 
value of 94%, indicating significant clinical usefulness as a screening instrument.
 81
 
Though, studies have revealed that visual and semi-quantitative valuation of perfusion CMR 
at 1.5-Tesla has moderate accuracy for detection of CAD, it is still mainly inadequate by low 
variances in contrast enhancement between normal and under perfusion myocardium. 
Compared to perfusion CMR at 1.5-T and 3-T systems distribute improved signal to noise 
ratio and contrast enhancement, which can be used to increase spatial resolution and image 
quality.
 82-87
 
MRI plaque description of the coronary arteries is exactly interesting because of small size 
and quick signal. Yet, plaque classification is easier in other vessels, for example the carotid 
artery is more classified than the coronary artery.
 88
  
 
1.2.3.3 Limitations 
 
CMR is recognised as a non-invasive method that allows complete valuation of cardiac 
pathology; however it can be inadequate due to relatively long acquisition times and the 
essential for ECG and respiratory gating. Recent developments include acoustic gating to 
cardiac sounds and gating from motion, which may increase image quality in patients with 
asymmetrical cardiac times, and decrease acquisition times. It is possible that growths in the 
approaching coming will allow fast acquisition of whole heart 3D data sets, with high 
temporal and special resolution, which can be recreated for additional analysis.  
Similarly, hopeful results for imaging coronary atherosclerotic plaques and more 
developments in spatial resolution can simplify clinically valuable imaging.
 89  
 Now, the 
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further technical and safety complications joint with compact contact to patients when 
performance procedures, limits the technique to highly specialised clinician and a decrease 
resolution of interventional CMR sequences. 
90
 
Certain patients will not be suitable for CMR. Several devices like pacemakers and 
implantable defibrillators could affect the performance of CMR, and all these have been 
considered as contraindication for CMR. Furthermore, obesity is one of the discontinue factor 
for CMR, due to a small diameter-size of the magnet.
 91
  
This is vendor-specific, and then in general a maximal body diameter of greater than 145cm 
will prevent CMR. Arrhythmias such as atrial fibrillation or frequent ventricular ecotype 
might compromise image quality and decrease diagnostic accuracy, even when heart rate 
control is optimal. More significantly patients with resting tachycardia may be unsuitable for 
stress perfusion CMR.
92
Another limitation of coronary CMR is the limited spatial resolution 
of MR imaging, which is less than 1.0 mm in z-axis direction. This is inferior to that of 
multislice CT angiography, which is between 0.4-0.5 mm. This limits the visualisation of 
distal coronary arteries and branches during coronary CMR.
 91
 
 
1.2.4 Coronary CT angiography 
 
Diagnosis of coronary artery disease with multi-detector computed tomography has become 
possible because of rapid developments in CT technologies. Multi-detector CT can produce 
images with high spatial and temporal resolution. Since the development of CT over the last 
three decades imaging of cardiac and coronary artery anatomy is significantly improved. The 
previous generations of CT scanners are limited in gantry rotation times, inferior spatial and 
temporal resolution which affect the accurate assessment of coronary artery diseases.  The 
performance of multi-detector row CT enables acquisition of cardiac images with thinner 
section thickness and reduced scan time. 
93,94
 
Multi-detector row CT systems are equipped with four or more parallel detector arrays and 
always apply a third generation technology with synchronously rotating tube and detector 
array. Dual slice detector systems was available in the early 1990s, but the systems with four 
detector arrays were introduced in 1998, and systems with eight, 10, 16, or more dynamic 
detector arrays were developed in 2001 and onwards.  
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1.2.4.1 Single-slice (single-detector) CT 
 
It was introduced in 1980s and became the most commonly used imaging modality in daily 
practice.
 95
  
Axial scanning requires long examination times because of the inter-scan delays necessary to 
move the table incrementally from one scan position to the next and unwind the cable, thus it 
is prone to misregistration or loss of anatomical details due to potential movement of the 
relevant anatomical structures between two scans (by patient breathing, motion or 
swallowing).
 95
   
Besides, only a few slices are scanned during maximum contrast enhancement when the 
contrast medium is used.  These problems may be overcome if the scan speed is increased 
and inters scan delay is eliminated. The development of multi detector CT possesses these 
features which help to overcome the above problems.
95
 
 
1.2.4.2 Four, eight and 16 detectors row CT 
 
In 1998, a 4-slice CT scanner was introduced by several manufacturers representing an 
obvious quantum leap in clinical performance. Since then, eight and 16 detectors row CT 
have been developed with improved temporal and spatial resolution, thus, making imaging of 
coronary arteries possible and improve as well. 
96
 
The major advantage of 16-slice scanners over 4-slice CT is the longer z-axis coverage (16 × 
0.75 mm vs 4 × 1.0 mm), resulting in significantly shorter breath hold and less motion 
artefacts. Coronary CT angiography became more clinically practical with retrospective 
electrocardiogram (ECG) gating to capture cardiac motion plus the z-axis coverage from 16-
detector row scanners. However, cardiac motion and stair-step artefacts are the main 
challenge in this system. Therefore, there are few steps suggested to overcome those 
problems, which include increasing the number of detector elements and the volume 
coverage along the z-axis of detector block. Moreover, increase in the sensitivity of detector 
material and application of iterative image reconstruction algorithms represents another 
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approach to improve cardiac image quality. During 2003 and 2004, manufacturers introduced 
different types of multi detector row CT models with less than 16-slice scanners, but most 
commonly the introduction of more than 16-slice scanners represented the main direction for 
improving multi detector row systems.
96-98
 
 
1.2.4.3 64 Detectors row Computed Tomography (64-MDCT) 
 
The introduction of 64 detector row CT scanner allows patients to be scanned with high 
resolution in 5 to 13 seconds with minimal or no motion-related artefacts. With gantry 
rotation times down to 0.33 second for 64 detectors row CT, temporal resolution for cardiac 
ECG-gated imaging is again markedly improved. The increased temporal resolution of 64 
detectors row CT has the potential to improve the clinical strength of ECG-gated cardiac 
examinations at higher heart rates, thereby reducing the number of patients requiring heart 
rate control. In contrast to previous studies, high diagnostic accuracy has been achieved despite 
the presence of severely calcified coronary plaques. In addition by using 64 detectors row 
CT, the scanning time is reduced to less than 15 seconds, allowing a decreased breath hold 
time, better utilization of contrast medium with fewer enhancements of adjacent structures 
and a lower dose of applied contrast medium. Improvement of image quality has also been 
reported in the visualization of all coronary artery branches with high sensitivity and 
specificity achieved.
99
 
The 64 detector row CT has sensitivity of 99% and the specificity of 95% when compared 
with coronary angiography. The 64 detector row CT was accurate and useful in non-invasive 
discovery of coronary artery stenosis. It had benefits with scanning, including decreased 
breath holding time compared with the 64 detectors row CT, fewer artefacts, and the quantity 
of contrast used was smaller than with previous CT scanners.
100 
  Another study indicated that 
the 64 detectors row CT has a diagnostic accuracy of 97%, sensitivity of 94%, and specificity 
of 97% in the detection of patients with coronary artery disease.
 100
 
The 64 detectors row CT is rapid and competent in screening for coronary artery disease. 
These changed in technology cause impacts imaging management significantly, decreases 
avoidable invasive challenging, saves time and cost-effectiveness. Also one of the benefits of 
the 64 detectors raw CT is possibly subsequent in preventable hospitalization.
 101
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The 64 detectors row CT is effective in giving rapid outcomes to health care benefactors by 
classifying patients with heart disease. Worldwide, 5 million patients were make appointment 
complaining of chest pain, therefore it is a need for using the 64 detectors row CT as a 
diagnostic screening instrument. The 64 detectors row CT is suggests a way to exclude 
disease, without exposing patients to the risks of an invasive procedure.
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Yet, the potential of the 64 detectors row CT in non-invasive cardiac diagnostics, many 
cardiologists referred patients with CAD to undergo cardiac CT.  
The main concern is radiation exposure to patients. The radiation dose for the 64 detectors 
row CT is reported to be about 14 mSv, and the dose for invasive coronary angiography is 6 
mSv. These radiation exposures produce period risks of 0.07% and 0.02%, individually, of 
making a serious cancer in the general population.
 102
 
Though the 64 detectors row CT involves a higher radiation dose from that practiced 
throughout a standard catheterization.  These complications were sum up to 0.13% overall 
risk of mortality from coronary angiography compared with the 0.07% risk from the 64 
detectors row CT.
102
 
 
1.2.4.4 Dual-Source CT (DSCT) 
 
The new generation of multi-detector row CT is Dual-Source; a current scanner with two x-
ray tubes and detectors providing an alternative method to increase temporal resolution.  The 
360° gantry rotation time is 280 ms, translating to a temporal resolution of approximately 75 
ms when the scanner operates with both x-ray tubes collecting data at the same energy.
103
 
The second-generation DSCT ―SOMATOM Definition Flash‖ was introduced in 2008. It 
features even faster gantry rotation (0.28 s), twice the number of detector slices and a larger 
field of view (332 mm) and a special spectral filter for dual-energy imaging. It has the high-
pitch acquisition mode (up to 3.4), only one phase is acquired, which gradually increases with 
the z-axis table translation. The influence on image quality for different clinical scenarios and 
heart rates is evaluated with the second generation dual-source CT.
104-110 
The diagnostic accuracy and image quality is mostly incomplete by coronary calcifications 
and motion artefacts in cardiac MDCT.
111-115
 Improved temporal resolution that results in 
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quicker gantry rotation speed and multi-segmental reconstruction algorithms has been helpful 
to obtain high diagnostic accuracy.
116
 A recent study stated that DSCT has a sensitivity of 
96%, specificity of 78%, a positive predictive value of68%, and a negative predictive value 
of 97%.
114 
DSCT coronary angiography with 350 mAs/rotation and 120 kV delivers mean 
effective dose of 8.8 mSv or 7.8 mSv, depending on the ECG pulsing algorithm used. 
117
 
Radiation dose is related to the protocols with reduced tube current to 20% outside of the 
pulsing window considerably with increasing heart rates, despite using wider pulsing 
windows at higher heart rates in order to maintain diagnostic image quality.  
Radiation dose reduces substantially at a considerably lower level with use of ECG-pulsing 
with saving of tube present to 4%, regardless of the heart rate throughout the 
examination.
117,118
 
 
1.3  Nuclear cardiology 
 
There are numerous indications that support the usefulness and effectiveness of myocardial 
perfusion imaging (MPI) and myocardial viability imaging (MVI) by different techniques for 
the management of patients with suspected or known CAD. In patients with suspected CAD 
non-invasive assessment is dependent on the primary detection of ischemia and its successive 
appearance.  To detect CAD, it is important to consider cost-effectiveness; optimal 
application of an imaging modality which enables an accurate evaluation of the incremental 
amount of information provided by an examination.  Currently, nuclear cardiology is widely 
used as a non-invasive method for evaluating myocardial perfusion and viability.
119
 
   
Myocardial perfusion imaging involves administration of radiopharmaceuticals or 
radioisotopes to display the circulation of blood flow in the myocardium. Perfusion imaging 
recognises areas of very concentrated myocardial blood flow related to ischemic change. The 
regional blood supply or perfusion can be measured either at rest, or through cardiovascular 
stress, or both. Imaging can also be achieved through emergent procedures.
120
 
Viability imaging is important to assess the degree of viable myocardial tissue. The scan is 
commonly accomplished in patients with earlier heart attacks, and the decision needs to be 
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made as to plan heart surgery which will offer substantial advantage. Perfusion and viability 
images can be completed with single photon emission computed tomography (SPECT), 
hybrid SPECT/CT and positron emission tomography (PET) or hybrid PET/CT techniques. 
These techniques use radiopharmaceuticals or radioisotopes that are removed and taken for a 
variable period of time by the myocardium. The data can be analysed by visual review or 
measurable techniques. 
120
 
There are a number of radiopharmaceuticals and isotopes which have been approved for use 
in myocardial perfusion imaging and myocardial viability including 
82
Rb (Rubidium-82), 
13
N-ammonia and 
18
F-FDG for cardiac PET, 
99m
Tc-tetrofosmin, 
99m
Tc-sestamibi and 
201
Tl-
thallium for cardiac SPECT in patients with significant coronary artery stenosis or abnormal 
coronary flow.
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1.3.1 Single Photon Emission Computed Tomography (SPECT) 
1.3.1.1 Imaging Principles 
 
SPECT uses techniques for constructing images which are acquired by planar images 
(typically in 64 × 64 or 128 × 128 data-point arrays) at many angles around the patient by 
single, dual, or three head scintillation cameras which are usually equipped with parallel-hole 
collimators, which offer plan views of the radioactivity from those angles. Normally, 120 
images are acquired at 3° increments for 360° SPECT (60 images at 3° increments for 180° 
SPECT in cardiac imaging). A single line of data in a planar projection image is a total 
profile of data developed from a slice of activity. 
121
 
Yet, consistent lines are clarified and back projected into an image space to concept an image 
of a transverse slice of the activity delivery as an array of totals at that slice place. SPECT 
images acquired are frequently used in oncologic applications and deliver physiologic 
information on localization of radiopharmaceuticals in the regions of interest. However, these 
images suffer from inferior spatial resolution and regularly deficiency anatomic 
developments for exact weaknesses of location of areas of abnormal uptake.
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Whereas, normal physiologic deliveries necessity frequently stay distinguished from regions 
of abnormal uptake. This technique lacks of anatomic landmarks for precise correlations. 
Also, a number of the difficulties in SPECT are encountered that would result from a 
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rebuilding of the data acquisition procedure. The reconstructed image shows an obvious 
reduction in activity that extent a minimum at the centre of the image. This result is due to 
attenuation of photons in the source earlier going the source and presence noticed by the 
camera system.
122-124
 
The camera systems, study protocols and data acquisition vary significantly in studies of 
different radioisotopes that were reported previously.  
Moreover, there is an issue in myocardial perfusion SPECT which was discussed in a clinical 
setting for long time regarding need to obtain high quality images in a short acquisition time.   
Surely, efforts are tried to find either   superior of data sampling using single and dual head 
data acquisition.
125,126
  Currently, dual head data collection is preferred, while single head 
data acquisition is still frequently used in a clinical practice.
127-130
 
According to the Bucerius J et al. indicated that concerning myocardial viability, positive 
predictive value for diagnosis of myocardial scar tissue was considerably higher for dual head 
data as compared to single head data acquisition.
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1.3.1.2 Diagnostic accuracy 
 
Subsequently, myocardial perfusion SPECT historical and exercise information is measured 
to produce incremental prognostic information for prediction of both cardiac death and follow 
up procedures.
132 
The SPECT has been reported to have a mean value of sensitivity of 82%, specificity of 76% 
and accuracy 83%.
133 
To detect a nonviable myocardium in patients with myocardial 
infarction using SPECT, the sensitivity was 69.4%, specificity was 81.8% and accuracy was 
79.9%.
134
 
A systematic review of sensitivity, specificity and the accuracy of SPECT, PET and PET/CT 
in the detection of CAD showed that PET demonstrated the highest sensitivity, specificity 
and the accuracy at 91%, 89% and 89%, respectively. Whereas PET/CT had 85%, 83% and 
88% while SPECT was found to have 82%, 76% and 83% corresponding to sensitivity, 
specificity and accuracy. 
133,134
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With the moderate results of sensitivity, specificity and accuracy in detecting CAD, therefore, 
this analysis indicates that SPECT has not reached the diagnostic accuracy to be considered 
as a reliable technique for assessment of CAD.
133
 
 
 
1.3.1.3 Limitations 
 
SPECT scanning can be time-consuming. It can take hours or days for the radiotracers to 
accumulate in some parts of the body under investigation and imaging may take up to several 
hours to complete though in some cases, newer equipment is available that can substantially 
shorten the procedure time.
135, 136
 
Several studies indicated that in patients with acute myocardial infarction (AMI) the reported 
rate of undetected infarcts by SPECT ranges from 11% to 25%.
136,137
  The spatial resolution 
of SPECT images is about 10 × 10 × 10 mm and it is similar to  the thickness of heart wall, 
non trans-mural infarcts are difficult to identify.
138,139
 
 
1.3.2 Hybrid SPECT-CT 
 
1.3.2.1 Imaging Principles  
 
The integration of SPECT and CT systems into a single imaging unit shares a common 
imaging stand and it offers an important improvement in technology since this combination 
of SPECT and CT data maximises the advantages of each imaging modality in the 
investigation of coronary artery disease. Therefore, the two datasets can be assimilated into a 
recorded plane by suitable corrections. Also, this combined acquisition of consistent slices 
from the two modalities. The CT data can be used to allow accurate assessment of tissue 
attenuation in the SPECT scans on a slice by slice origin. And the CT data are presented in an 
advanced resolution matrix than the SPECT data.
 140
  
It passes through more tissue and clarifying of the beam to eliminate low energy photons is 
essential. The causing spectrum has an actual energy of about 70 keV. Since attenuation 
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effects differ with energy, it is necessary to adapt the attenuation data developed with CT to 
equivalent the energy of the radionuclide required in the SPECT acquisitions.
 140
  
Yet, it is essential to adapt the attenuation data measured at an actual energy of 70 keV to 140 
keV for 
99m
Tc.   
This is typically by spending a bilinear model related attenuation coefficients at the required 
energy to CT numbers which are measured at the actual energy of the CT beam of x-rays. 
There are various benefits in the use of CT data for attenuation correction of emission data.
140
 
Firstly, the CT scan offers a high photon fluctuation that considerably decreases the statistical 
noise related to the correction in contrast to other techniques. Similarly, due to the quick 
acquisition rapidity of CT scanners, the overall imaging time is considerably reduced by 
using this technology. Also, one of the advantages associated with the high photon 
fluctuation of CT scanners is that attenuation measurements can be made in the attendance of 
radionuclide distributions with insignificant influences from photons produced by the 
radionuclides.
 141
  
The use of CT also eliminates the need for additional hardware and transmission sources that 
often must be replaced on a routine basis. 
 
The anatomic images developed with CT can be 
fused with the emission images to deliver useful anatomic records for correct local area of 
radiopharmaceutical uptake.
141
 
The assessment of patients with symptoms of chest pain with coronary CT angiography only 
proves a low specificity and PPV. The use of hyprid SPECT-CT imaging results in a marked 
increase in specificity and PPV to distinguish haemodynamically significant coronary lesions. 
SPECT-CT combined improves the diagnostic value of coronary CT angiography and 
encourage physiology built development of interventional processes in patients with 
established CAD.
142
 
 
1.3.2.2 Diagnostic accuracy 
 
Rispler S et al. reported that for assessment of hemodynamically significant coronary artery 
lesions, integrated (SPECT-CT) had sensitivity, specificity, PPV and NPV of 96%, 95%, 
77% and 99%, respectively.
143
 SPECT/CT imaging results in improved image quality, 
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showing improved specificity and PPV to detect hemodynamically significant coronary 
lesions in patients with chest pain.
143
 
The anatomic evidence found with CT matches the functional assessment delivered by 
SPECT together from a diagnostic and prognostic perception. Numerous procedures for 
combination of the CT CACS with SPECT have been planned.
144
 
Hybrid SPECT-CT and PET-CT are non-invasive imaging modalities cardiovascular that 
quickly progress with ability to image the structure and function in the heart and 
cardiovascular system.
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It is determining direct measurable evidence almost myocardial perfusion and metabolism 
with coronary and cardiac anatomy; hybrid imaging offers the prospect for a complete non-
invasive assessment of the problem of atherosclerosis. Also, it’s provided physiological 
significances in the coronary arteries and myocardium. 
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The benefits of prospective study will be to refine these technologies, to establish standard 
protocols for image acquisition and interpretation, to address the issue of cost-effectiveness, 
and to confirm a variety of clinical uses in fluctuated clinical decisions.
146
 
The conception of joining SPECT studies with CT developed throughout a single 
examination has encouraged productive elementary and clinical investigation in a selection of 
diseases.
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1.3.2.3 Limitations 
 
Though, the number of integrated SPECT-CT systems remains to grow at a slightly increased 
rate, the development of SPECT-CT did not monitor the similar movement. One of the main 
reasons for the slow receiving of SPECT-CT compared to PET-CT is the comparative cost of 
SPECT and CT which takes into account the low portion of clinical suggestions where 
SPECT-CT is required
147
. 
There are new technological and precise expansions enhance substantial difficulty to the 
current, dynamic discussion almost the possible of conventional, single photon imaging to 
survive the experiments rising from PET imaging. Since that PET is greater to single photon 
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imaging for examining the area distribution of agents and as the growing variety of PET 
radiopharmaceuticals.
148
 
 
 
1.3.3 Positron Emission Tomography (PET) 
1.3.3.1 Imaging Principles 
 
Cardiac positron emission tomography (PET) imaging has progressed rapidly from an initial 
research instrument to an applied, high performance clinical imaging modality.   
The wide availability of PET, the commercial accessibility of perfusion and viability PET 
imaging radiopharmaceuticals, benefit for PET perfusion and viability procedures by 
government and private health insurance strategies, and the accessibility of computer 
software for image demonstration of perfusion, wall motion, and viability images represent 
the advantages of PET camera. All of these have been a key to cardiac PET imaging which 
enables it to be attractive for a routine clinical instrument. 
Although, myocardial perfusion PET imaging is selected to study patients requiring stress 
perfusion imaging, there are detectible patient individuals hard to image with conventional 
SPECT imaging that are principally possible to benefit from PET imaging. For example,  
obese patients, women, patients with previous no diagnostic tests, and patients with poor left 
ventricular function attributable to coronary artery disease measured for revascularisation. 
Myocardial PET perfusion imaging with rubidium-82 is significant for high efficiency, rapid 
quantity, and in a high volume setting, low operating costs. PET metabolic viability imaging 
remains to be a non-invasive typical for diagnosis of viability imaging. Cardiac PET imaging 
has been exposed to be cost-effective. The possible of routine quantification of resting and 
stress blood flow and coronary flow reserve in relation to pharmacologic and stress provide 
teasing potentials of increasing the power of PET myocardial perfusion imaging. This can be 
concluded by providing declaration of stress quality control. 
149
 
Also, in improving diagnosis and risk stratification in patients with coronary artery disease. 
PET has increasing diagnostic imaging into early coronary artery disease and endothelial 
dysfunction issue to risk factor variation.
 150 
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While, the clinical value of cardiac PET imaging was established twenty years ago, PET 
imaging varies from conventional radionuclide imaging. Since, it uses radionuclides that 
decay with positron emission. A positron has the identical quantity as an electron but has a 
positive responsibility. 
150-152
   
The positron movements a short space, up to a few millimetres, interrelates with an electron, 
and the two experience a joint annihilation, subsequent in the making of two 511-kev gamma 
photons, 180° apart from each other. PET imaging involves of discovery of these photons in 
chance. PET imaging is electronic accident localisation by ring detector indications to high 
acquisition efficiency.
153
 
These outcomes in high-quality images developed in a short time and many sequential 
achievements. The short half-life of 
82
Rb and 
13
N ammonia effect in low radiation exposure 
for the patient from numerous involvement studies or follow-up studies and allow other 
radionuclide imaging studies on the same day. A consequence of the ability of PET to 
perform effective non-uniform attenuation correction is high image consistency, therefore 
reducing attenuation artefact.
 154
 
The capability to calibrate the PET system allows quantification of myocardial flow and 
glucose application. PET imaging provides an actual high resolution of 5 to 7mm, parallel 
with 15mm with resolution of SPECT imaging though in cardiac imaging, resolution is 
reduced by respiratory and cardiac wall movement. Cardiac PET imaging offers the full 
potential resolution.
155
 
Myocardial PET perfusion imaging requires patient preparation for stress and rest which is 
similar to SPECT perfusion imaging. Myocardial PET perfusion imaging is frequently 
achieved with pharmacologic-induced stress, mainly with dipyridamole or adenosine.
155
  For 
myocardial FDG PET viability imaging, this is performed with glucose filling and additional 
insulin. The patient is injected with FDG. After for a 1-h rest, the patient then undergoes 
emission PET imaging, along with a transmission scan.
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1.3.3.2 Diagnostic accuracy 
 
PET perfusion scan indicates an outstanding prognosis with a low proportion of cardiac 
procedures.
157-159 
At the 70% stenosis severity, sensitivity was 87% for PET and specificity 
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was 100%, with a resulting significant improvement in overall accuracy of 89%.
160
  While, at 
the 50% stenosis severity, sensitivity was 79% for PET and specificity was 100%, with a 
resulting significant improvement in overall accuracy by 87%.
160 
There are numerous details why PET influence further SPECT for gated cardiac perfusion 
imaging. SPECT image superiority arises through low myocardial amounts, soft tissue 
decrease, and scatter of movement from nearby structures such as the liver and bowel into the 
cardiac region of concern. PET equipment offers superior myocardial amount mass in a 
greatly shorter acquisition time.
161,162
 
Spatial resolution of PET is in the range of 2 to 4 mm, as is observed with 6 to 8 mm for 
99m
Tc SPECT. Currently, image resolution is dependent on several patient and processing 
factors and it ranges from 6 to 10 mm and 10 to 14 mm, individually. The most significantly 
moving PET effective resolution is the positron range, which gives a characteristic shadow to 
the images not existing with the gamma emissions of SPECT.
 162
  
82
Rb has relatively high positron emission energy (1.52 MeV), with a mean range of 
approximately 5.5 mm. One effect of the higher spatial resolution of PET is better parting of 
the heart from nearby structures and there is less scatter result on myocardial totals. Once 
there is hot movement in near to the heart in SPECT scans, the filtered back projection 
method of reconstruction can outcome in artefacts that perform as perfusion defects.
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1.3.3.3 Limitations 
 
Yet, PET reconstruction uses an OSEM algorithm, which does not present the ramp-filtering 
artefact
163
. Patient exposure to radiation is significantly lower with 
82
Rb PET related with 
rest/stress 
99m
Tc SPECT.
164,165
 
 
1.3.4 Hybrid PET-CT 
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1.3.4.1 Imaging Principles 
 
In spite of the fact that the introduction of dual-modality imaging systems planned exactly for 
medical exercise is quite new.  The possible advantages of joining anatomical and functional 
imaging have been accepted for numerous years by radiological scientists and physicians.
166
  
Several of the developers of nuclear medicine accepted that a radionuclide imaging system 
might be increased by count peripheral radioisotope basis to obtain show data for anatomical 
association of the emission image. 
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But, the theoretical plans were never concentrated to practice or applied in any an 
experimental or a clinical background until established in the 1990s the progress of 
SPECT/CT and coming established in 1998 the improvement of combined PET/CT imaging 
systems, which have the ability to detected individually radionuclide and CT data for 
connected functional structural imaging
167-170
.  
Later, SPECT/CT and PET/CT dual-modality imaging systems were presented by the main 
scanner manufacturers for routine clinical practice where about more than 80% of PET 
systems sold yearly are combined PET/CT units. Dual-modality SPECT/CT and PET/CT 
scanners now are available from all of the major medical imaging department’s producers 
(GE Healthcare Technologies, Siemens Medical Solutions, and Philips Medical Systems) 
contribution the show obtainable on state-of-the-art diagnostic CT systems.
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1.3.4.2 Diagnostic accuracy 
 
Many SPECT/CT systems join a dual-headed SPECT camera fixed to a single detector, 4 
detectors, 8 detectors or a 16 detectors diagnostic CT scanner however present PET/CT 
systems have up to 64 slice CT ability. It has detectors with either 2D/3D or only 3D PET 
imaging capability. This is demonstrates a high resolution anatomical information from CT. 
Also, dual-modality imaging compares functional and anatomical data to progress disease 
zone and helps management development for radiation oncology or surgery. 
171-175
 
A current study using PET/CT indicated that a sensitivity of 93%, a specificity of 83%, with a 
regularity rate of 100%. In this study of patients without known previous CAD, the PPV and 
NPV of PET/CT were 80% and 94%, respectively, with an overall accuracy of 87%. 
176  
In 
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addition, both SPECT/CT and PET/CT have confirmed their capability to enable attenuation 
correction by a patient particular attenuation map resulting from CT. It can be produced faster 
and more accurately than attenuation maps generated with external radionuclide sources. 
177
 
PET scanners have intense enhancements in routine over the past years. Dual modality, these 
developments are in together hardware and software, with new radiopharmaceuticals, 
improved spatial resolution, advanced sensitivity, more accurate reconstruction techniques, 
and the newer-establishment of time of flight measurements. 
As the improvements in PET technology confirm a more stable examination; a whole 
PET/CT inspection can currently be done in 10–15 min. An increasing supports the better 
accuracy of performance with PET/CT, associated with any CT or PET developed 
individually.
178,179
  
There are significant developments in specificity and, sensitivity and in early detection of 
CAD. These are enhancements that are related with a technique (PET) that previously 
establishes high levels of sensitivity and specificity for an extensive disease states. The 
sensitivity that software combination is a viable another to PET/CT and certainly offers 
several advantages.
180
  
Software combination techniques will continuously have a clinical role, improving the 
registration of images developed with PET/CT, supporting images from modalities if there is 
no alternative hardware solution and combining PET/CT images with MRI for treatment 
development. Combination software may be extensively obtainable, however that is not the 
similar as being normally accessible.  
It is the routine, practically easy, accessibility of registered CT and PET images for every 
patient that gives PET/CT the advantage. PET/CT operators have just been combined by a 
increasing of SPECT/CT users. The distribution of PET/CT and SPECT/CT into the clinical 
practice has been determined by physician request founded on gradually fixed clinical results. 
As long as this movement remains, the future of hybrid imaging and of PET/CT, in particular, 
will be guaranteed.
178,179
 
 
1.3.4.3 Limitations 
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PET/CT combined equipment cannot determination entirely the matters related with precise 
position of two modalities.
 180 
The use of CT for attenuation correction may create artefacts that do not appear with a 
conventional radionuclide scan. Moreover, there is debate connected to some extra radiation 
dose associated with using the CT scan.  
This situation has created the application for preparation of separately the technologists and 
the physicians. Instructions have been available and new ethics recognised making an actual 
dissimilar condition currently from the technique radiology and nuclear medicine was 
worked.
180
 
Furthermore, addressing the training of practician for a different feature in imaging is 
essential. While, the original PET/CT strategies might have performed too expensive by 
joining two costly modalities. Also, high performance PET/CT scanners are now accessible 
for a financial amount similar to that of various PET alone earlier 2001. The most worry that 
the 45 min PET scan would create sufficient use of the related CT scanner
182
.  
 
1.3.5 Radioisotopes used for nuclear cardiology used for SPECT/ SPECT-CT 
 
A patient who has significant coronary artery stenosis or abnormal coronary flow 
replacement will have a region of reduced radiopharmaceutical absorption in the area of quite 
reduced perfusion. Each of the area or the severity of reduced tracer absorption is inferior 
when the tracer is controlled through stress and at rest.  The region of reduced tracer 
absorption is recorded due to ischemia. If the region of reduced tracer absorption is still 
unaffected from rest to stress, it is most likely that the defect is scar.  While, in particular 
circumstances it could characterise viable, under-perfused myocardium. Abnormalities may 
also indicate high obstruction to regions of viable, about myocardium. The available SPECT 
flow agents are considered a quick myocardial abstraction by a cardiac uptake related to 
blood flow. 
 
1.3.5.1 99mTc-tetrofosmin 
 
38 
 
99m
Tc labelled tetrofosmin is relative to regional myocardial blood flow with a first-pass 
extraction portion inferior to that of 
201
Tl and sestamibi. Myocardial uptake is relative to 
blood flow completed the physiological range of blood flow. 
 Blood flow and tetrofosmin myocardial movement demonstrate a direct relationship to about 
2 mL/min/m.   For sestamibi, tetrofosmin uptake is not direct related to the growing blood 
flow.  
Also, tetrofosmin establishes a table during stress at a blood flow level inferior to that of 
sestamibi.
181
 During intravenous injection tetrofosmin is cleared quickly from the blood. 
Myocardial subtraction from the blood into the myocardium is less effective than for 
201
Tl.  
Tetrofosmin is similar to sestamibi which is considered by a speedy heart uptake and stable 
holding, no evidence of reorganisation for up to 3 hours next injection within reversible 
ischemic segment. Tetrofosmin is offers the similar benefits of sestamibi concerning the 
energy level. The half-life and the larger doses can be controlled to the patient in evaluation 
with 
201
Tl. 
184
  
99m
Tc-tetroforsmin intravenously administrated with an activity of 740–1,480 
MBq (20–40 mCi) and effective dose of 0.0067 mSv/MBq (0.025 rem/mCi). 
 
1.3.5.2 99mTc-sestamibi  
 
99
Tc labelled sestamibi is related to area myocardial blood flow with a first-pass extraction 
fraction lower than that of 
201
Tl. Yet, the considerably higher dose of sestamibi used more 
than inferior removal as associated to 
201
Tl. The relationship between regional blood flow and 
myocardial uptake is to almost 2 mL/min/m.
185
 A sestamibi myocardial uptake is not directly 
related to  growing flow. The myocardial management of sestamibi is associated with screen 
across biological membranes.
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After sestamibi collects inside the myocardial cell, it is sure in a quite stable method. The 
parenchymal cell absorbent and volume of supply of sestamibi are much superior to 
201
Tl.  
Subsequent, in a longer time is inside the myocardial cells for sestamibi. Thus, at clinical 
imaging following tracer injection, remaining myocardial tracer satisfied is related for 
201
Tl 
and sestamibi is higher and more rapid extraction of 
201
Tl. Sestamibi has uncertain indication 
of variance from ischemic to normal tissue. So, images achieved at 1 hour reproduce 
perfusion at the time of injection. The 
99
Tc energy level (140 KeV) is perfect for imaging 
39 
 
with conventional gamma camera, reducing difficulties for soft tissue reduction.  Besides, the 
6 hours half-life gives a higher dose that can be managed to the patient as related to 
201
Tl. 
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99
Tc-sestamibiis intravenously administrated with an activity of 740–1,480 MBq (20–40 mCi) 
and effective dose0.0085 mSv/MBq (0.031 rem/mCi). 
 
1.3.5.3 201TI-thallium 
 
Thallium-201 (
201
TI) is relative to area myocardial blood flow with a high first-pass removal 
in the range of 85%. The relative between blood flow and myocardial uptake is practically 
direct at low and sensible flow level, to at least 3 mL/min/gm. Also, there achieves to be a 
decrease in the uptake of 
201
Tl in relation to blood flow. But, at almost 3 mL/min/gm, there is 
a table result such that, growths in blood flow, 
201
Tl movement does not have variation. The 
growth and absorbent of 
201
Tl inside the myocardium is affected by together coronary blood 
flow and cellular viability. Yet, an intracellular uptake of 
201
Tl across the sarcolemma 
membrane is continued for as extended as essential blood flow. Blood flow current to 
transmit the tracer to the myocardial cell. After,
201
Tl has arrived into myocardial cells; a 
continuous altercation precedes location through the cell membrane. 
In the presence of an ischemia, the essential degree for 
201
Tl is concentrated. This gives to 
viable of late tracer activity between originally ischemic and normally perfused areas. That is 
stated to as tracer redistribution. Later 
201
Tl injection, the initial images acquired reproduce 
the area distribution of myocardial blood flow. In spite of 
201
Tl has been the maximum used 
tracer to measure myocardial blood flow, its physical features represent model. The energy 
level (69 to 83 KeV) is slightly appropriate for imaging by conventional gamma camera. It 
creates particular difficulties for attenuation in the body.  
The quite extended physical half-life 73 hours and biological half-life 10 days principal to a 
radiation dose to the kidneys and only a small amount (74 to 111 MBq) of 
201
Tl can be 
controlled.
187
 
201
Tl-thallium is intravenously administrated activity of 74–148 MBq (2–4 
mCi) and effective dose of 0.23 mSv/MBq (0.85 rem/mCi). 
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1.3.6 Radiopharmaceuticals used of nuclear cardiology used for PET/ PET-CT 
 
The capabilities of radionuclide methods are to measure myocardial perfusion or viability in 
the incidence of coronary artery stenosis. This is associated to the myocardial supply of a 
perfusion tracer and consistent regional blood flow. 
Consequently, myocardial perfusion can be imaged and hypo-perfusion can be distinguished 
as a relation uptake defect as associated with the usually perfused myocardium. In addition, 
dissimilar PET tracers could be used for the measurement of qualified myocardial blood flow 
and Coronary Flow Reserve (CFR).  
Although, several tracers have been used for evaluating myocardial perfusion with PET, the 
most widely used in clinical practice are as listed on the following subtopics.
188
 
 
1.3.6.1 Rubidium-82 (82Rb) 
 
82
Rb is apotassium equivalent that is a generator produced with a half-life of 76 s and moving 
stuffs related to
201
Tl. The different benefit of not requiring a cyclotron, 
82
Rb is the 
extensively used radionuclide for assessment of myocardial perfusion with PET.  Next, 
intravenous injection of 
82
Rb quickly crosses the vessel membrane.
187
 Myocardial uptake of 
82
Rb needs dynamic passage through the sodium and potassium adenosine triphosphate 
transporter. It is dependent on coronary blood flow.
189
  
The only vessel passage extraction portion of 
82
Rb exceeds 50%. Nevertheless, its remaining 
removal portion declines in an indirect method with growing myocardial blood flow 
190
.The 
determined dynamic energy of positrons produced through
82
Rb degeneration is considerably 
higher than that of 
18
F or 
13
N. Thus, the spatial improbability in the position of the decaying 
nucleus which depends on the moved by the positrons earlier their extermination is more for 
82
Rb 2.6-mm complete width at half extreme than for 
18
F 0.2 mm or 
13
N 0.7 mm.  
While,
82
Rb imaging produces an excellent image quality with current PET technology. Its 
longer positron variety and short half-life needs important image quality to suppress noise. 
Individually alleviate slightly the better quality spatial resolution of PET.
191
 Rubidium-82 
(
82
Rb) is intravenously administrated with an activity of 1,100–1,850 MBq (30–50 mCi) and 
for effective dose of 0.0048 mSv/MBq (0.018 rem/mCi). 
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1.3.6.2 13N-ammonia  
 
13
N-ammonia is a cyclotron produced and a half-life of 9.96 min. 
13
N-ammonia quickly no 
display from the movement, positive the acquisition of images of excellent superiority. 
Though, the appropriation of 
13
N-ammonia in the lungs is usually minimal, it may be 
enlarged in patients with low left ventricular (LV) systolic function or chronic pulmonary 
disease. This might be in shot affect the excellence of the images.  
It could be essential to rise the time between injection and image accomplishment to enhance 
the contrast in myocardial.
13
N-ammonia contains of neutral ammonia NH3 in stability with its 
stimulating ammonium NH4 ions. The neutral NH3 particle is readily through plasma and cell 
membranes; this is leading to almost removal from the vascular pool.
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13
N-ammonia is combined into the glutamine pool and develops metabolically surrounded. 
It’s retaining by the myocardium an indirect and opposite association with blood flow. The 
portion of 
13
N-ammoniaengaged by the myocardium throughout its principal pass is 0.83 
when blood flow is 1 mL/min/g, and reductions to 0.60 as flow rises to 3 mL/min/g.
193
 
The remaining tissue removal reduces as myocardial blood flow growths. 
13
N-
ammoniarelative between remaining tissue extraction and blood flow is direct for standards 
of blood flow up to 2.5 mL/min/g. A metabolic trapping of 13N-ammonia develops the rate 
restrictive factor moving tracer retention. This is indication to under assessment of blood flow 
at high flow rates.
194
  
Consequently, to quantify myocardial blood flow using 
13
N-ammonia, it develops essential to 
accurate for flow dependent fluctuations in remaining tissue removal. Myocardial retaining of 
13
N-ammonia is dissimilar the lateral left ventricular (LV) wall being about 10% lower than 
that of other segments, even in healthy subjects. 
13
N-ammonia images can be low-quality by 
infrequent powerful liver activity. It cause affect with the assessment of the inferior wall. Yet, 
the appropriation of 
13
N-ammonia in the lungs is commonly insignificant. It could be 
improved in patients with low LV systolic purpose or chronic pulmonary disease.
195
 
It could be essential to growth the time between injection and image acquisition of the 
contrast amongst myocardial and background activity. 
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13
N-Ammonia allows the acquisition of no gated and gated images of good quality. These 
studies take complete benefit of the higher resolution of PET qualified to SPECT, as the half-
life of 
13
N is adequately extended. Its usual positron variety is very short. 
 Gated 
13
N-ammonia imaging can deliver exact assessments of both regional and overall 
cardiac function. But, this imaging agent is not well suitable for peak stress gated imaging. 
For the reason that of the 3- to 4-min time interval between radiotracer injection and the start 
of imaging with the quite long 20 min acquisition times.
196
 
13
N-ammonia is intravenously 
administrated with an activity of 370–740 MBq (10–20 mCi) and effective dose of 0.0022 
mSv/MBq (0.0081 rem/mCi). 
 
1.3.6.3 18F-FDG 
 
Myocardial imaging using 
18
F-FDG is the greatest recurrent clinical request of cardiac PET. 
It is achieved in patients with dysfunctional, hypo-perfused myocardial regions to indicate the 
possibility of advantage from revascularisation. Remaining metabolic activity is a meter of 
myocardial viability, and therefore of reversibility of contractile dysfunction.  
18
F-FDG has a better regional uptake which makes it most suitable for assessing myocardial 
perfusion and viability. However, regional reduction of 
18
F-FDG uptake in quantity to 
perfusion is shows irreversibly damaged myocardium. 
Myocardial 
18
F-FDG uptake can be imaged by SPECT using extreme high energy 
collimators. Methodological issues specific to SPECT need to be measured for image 
interpretation.  
This also relates to combinations of SPECT perfusion imaging and 
18
F-FDG PET imaging for 
viability assessment. Cardiac PET has been accessible for a quite short time and the 
techniques have been under quick progress. Also, some studies reported the actual tasteless 
patients who are typical applicants for cardiac PET.
197,198
 
18
F-FDG is intravenously 
administrated with an activity of 350 – 750MBq (4.5-6 mCi) and effective dose of 0.027 
mSv/MBq (0.10 rem/mCi). 
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1.4 Thesis outline  
 
This thesis contains seven chapters. An overview of background, different imaging 
modalities and radiopharmaceuticals/radioisotopes is presented in this chapter which consists 
of the relevance and the interconnection to the topic of nuclear cardiology in the diagnosis of 
coronary artery disease. The overall aim of this thesis is to investigate the recently developed 
imaging technique, PET with regard to its diagnostic value in the assessment of coronary 
artery disease. This technique is compared to the standard method cardiac SPECT in terms of 
diagnostic value of myocardial viability. 
Chapter 2 is a systemic review of the diagnostic value of SPECT, PET and PET/CT in the 
diagnosis of coronary artery disease. The analysis of all eligible articles shows that PET has 
the highest diagnostic value in the diagnosis of coronary artery disease. 
Chapter 3 is a head to head comparison of the coronary calcium score by computed 
tomography with myocardial perfusion imaging in predicting coronary artery disease. 
Research findings of this study show that coronary calcium score and SPECT provide 
complimentary information, thus should be used together in the diagnostic management of 
patients with coronary artery disease. 
Chapter 4 is a phantom experiment on the myocardial perfusion imaging using 
99m
Tc-
sestamibi SPECT. A cardiac phantom is manufactured to simulate the normal cardiac 
anatomy, and myocardial perfusion imaging with SPECT is tested on the phantom. Results 
indicate that the cardiac phantom can be used for further experimental studies, in particular 
cardiac SPECT and PET imaging. 
Chapter 5 is a prospective study on diagnostic value of 
18
F-FDG PET in the assessment of 
myocardial viability in comparison with 
99m
Tc SPECT and echocardiography with invasive 
coronary angiography as the gold standard. Patients with known or proven coronary artery 
disease are recruited to undergo all of these imaging examinations. Results show that 
18
F-
FDG PET has high diagnostic value in myocardial viability assessment when compared to 
SPECT or echocardiography, and it can be used as a reliable and accurate modality in 
diagnosing coronary artery disease and guiding patient management. 
Chapter 6 is a summary and conclusion of the thesis. 
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Chapter 2  Diagnostic value of SPECT, PET and PET/CT in the diagnosis 
of coronary artery disease: A systematic review 
 
2.1 Introduction 
 
Coronary artery disease (CAD) remains the leading cause of mortality and morbidity in 
Western countries. 
1
Invasive coronary angiography is currently the gold standard for 
diagnosis and treatment of CAD; however, it is an invasive procedure associated with risks 
and complications. 
2
Moreover, it is reported that around 20% to 40% of all diagnostic 
invasive coronary angiography procedures were performed for diagnostic purposes without 
any interventional procedures being applied, 
3-5
 Thus, investigation of less invasive imaging 
modalities is important for reducing or avoiding the use of invasive coronary angiography 
examinations. 
6
 
Currently, multislice computed tomography (CT) angiography is widely used in clinical 
practice for the diagnosis of CAD, and its diagnostic accuracy has been significantly 
enhanced with the recent development of64-, 256- and 320-slice scanners.
7-10 
Studies have 
shown that multislice CT angiography can be used as are liable alternative to invasive 
coronary angiography in selected patients, due to its high sensitivity and specificity. 
7-10
  
Myocardial perfusion imaging with SPECT is a widely established method for non-invasive 
evaluation of coronary artery stenosis.
11
 However, the most important applications of SPECT 
are in the diagnosis of CAD, prediction of disease prognosis, selection of patients for 
revascularisation and assessment of acute coronary syndromes. Moreover, SPECT holds 
special value in some particular patient subgroups.
11-13 
Generally speaking, the sensitivity of 
stress SPECT for detecting angiographically-defined CAD is consistently above 70%, but in 
the better-designed studies, it is within the range of 85-90%.
14, 15 
Positron emission tomography (PET) has contributed significantly to advancing our 
understanding of heart physiology and pathophysiology for more than 25 years. The 
diagnostic accuracy of myocardial perfusion by PET in the assessment of CAD has been 
reported to be superior to SPECT.
16-17 
PET with rest-stress myocardial perfusion is regarded 
as an exact imaging modality for diagnosing and managing patients with CAD.
17  
Moreover, 
the combined modality of PET/CT further increases the diagnostic accuracy in CAD.
13-17
 
58 
 
Despite promising results reported in the literature,
18, 19
 the diagnostic value of SPECT and 
PET to detect CAD has not been well established. This is mainly due to the fact that the 
diagnostic accuracy reported by these studies is variable and the radiopharmaceuticals used in 
these studies are different. Thus, the purpose of our study was to investigate the diagnostic 
value of SPECT, PET and PET/CT when compared to invasive coronary angiography for 
detection of CAD, based on a systematic review of the current literature. 
 
2.2  Materials and methods  
 
A search of the English-language literature was performed using two main databases, 
PubMed/Medlineand Science Direct. The search included articles published between 1985 
and 2009 on the topics of SPECT, PET and PET/CT in CAD. The research was limited to 
peer-reviewed articles on human subjects and studies published in the English language. The 
keywords used for the search were ―Positron Emission Tomography‖, ―Single Photon 
Emission Computed Tomography‖, ―integrated Positron Emission Tomography and 
Computed Tomography‖, ―Coronary Artery Disease‖, ―Myocardial perfusion‖, ―Nuclear 
Medicine Imaging in cardiac disease‖.  
The reference lists for studies matching these criteria were also reviewed to identify 
additional articles which were not found through the initial search. The last search was 
performed in September 2010 to ensure inclusion of all recent publications in the analysis. 
Articles that met the following criteria were included for analysis: SPECT, PET, or PET/CT 
studies were performed in patients who underwent myocardial perfusion imaging (MPI) 
rest/stress test while invasive coronary angiography was used as the standard of reference; at 
least ten patients were included in each study; diagnosis of CAD was based on >50% 
stenosis. 
The reason >50% stenosis was chosen was because it has become a routine clinical practice 
to consider coronary stenosis >50% as haemodynamically significant.
20-22
Also, the diagnostic 
value in terms of sensitivity and specificity was reported in the study. The exclusion criteria 
included: review articles or case study reports; animal or phantom studies; studies dealing 
with myocardial perfusion without addressing the diagnostic accuracy of coronary artery 
stenosis or occlusion, and studies including patients treated with coronary stents or bypass 
grafts. 
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Two reviewers checked the references independently and the following information was 
extracted from each study: year of publication; number of participants in the study; 
prevalence of patients with suspected or confirmed CAD; mean age; percentage of male 
patients affected; type of radiotracer used in each study; rest and stress imaging protocols; 
diagnostic value of SPECT, PET and PET/CT in terms of sensitivity and specificity; and the 
accuracy of SPECT, PET and PET/CT for detection of CAD.  
The main findings were summarised in terms of the extent to which studies were reported to 
have shown the value of using SPECT, PET and PET-CT to diagnose CAD towards 
improving patient management and cost-effectiveness. All of the statistical analyses were 
undertaken using SPSS software version 17.0 (SPSS Inc., Chicago, ILL).Each of the study 
estimates for sensitivity and specificity were independently combined across studies using 
one sample test. Comparison was performed by Chi Square test using n-1 degree of freedom 
to test if there are any significant differences between different imaging modalities (SPECT 
vs PET, SEPCT vs PET/CT, PET vs PET/CT). Statistical hypotheses (2-tailed) were tested at 
the 5% level of significance. 
 
Figure 2.1 Flow chart shows the searching strategy of eligible References. 
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2.3 Results 
 
Twenty-five studies (with 25 comparisons) met the selection criteria and were included in the 
analysis.
20- 44
Ten of these studies were performed with SPECT alone,
20-25, 40-42, 44
while six of 
the studies were performed with PET alone.
31-36
Five studies were carried out with both PET 
and SPECT modalities 
26-30
and the remaining four studies were investigated within teg rated 
PET/CT.
37-39, 43
 
The total number of patients included in these studies was 4,114 with 53.5%of the patients 
suspected of CAD, 72.2 % being male and the mean age of patients being 48-years-old. Table 
2.1 summarises the number of patients, the radiotracers used in each study, and the reported 
sensitivity, specificity and accuracy with use of SPECT, PET and PET/CT imaging 
modalities, respectively. 
 
Figure 2.2 Overall pooled mean diagnostic values of SPECT, PET and PET/CT for detection 
of coronary artery disease. 
 
The degree of coronary artery stenosis was assessed based on the criterion of >50%, which 
was determined by invasive coronary angiography in all studies.  
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Of these 20 studies, 
82
Rubidium was the most commonly-used radiopharmaceutical which 
was utilised in 10 studies;
27–29, 31-34, 37-39 99
mTc-Sestamibi was used in seven studies;
20-22, 24, 25, 
27, 42201
Thallium was used in four studies;
26, 27, 29, 30
a combination of
201
Thallium and 
99
mTc-
Sestamibi was used in one study;
23 99
mTc-Tetrofosmin was used in three studies;
40, 41, 44
 and 
combinations of 
13
N Ammonia and 
82
Rubidium were used in the remaining two studies.
35,36
 
Analysis of diagnostic value of SPECT in CAD  
A total of 2,208 patients were included in 15 SPECT studies based on significant CAD which 
was determined by visual assessment of coronary angiography. Figure 2.2 shows the mean 
sensitivity, specificity and accuracy of SPECT for diagnosis of CAD. As shown in the figure, 
the diagnostic value of SPECT was moderate when compared to invasive coronary 
angiography. 
Analysis of diagnostic value of PET in CAD 
 A total 1,376 patients were included in another 11 studies performed with PET tests based on 
significant CAD which was determined by visual assessment of coronary angiography. 
Figure 2.3 shows the mean sensitivity, specificity and accuracy of PET for diagnosis of CAD. 
As shown in the figure, PET imaging was found to have high diagnostic value in the 
detection of CAD. 
Analysis of diagnostic value of PET/CT in CAD  
A total 518 patients were included in four studies performed with PET/CT studies based on 
significant CAD which was determined by visual assessment of coronary angiography. Again 
Figure 2.4 demonstrates that moderate sensitivity, specificity and accuracy of PET/CT were 
reached for diagnosis of CAD. 
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Table 2.1 Study characteristics of SPECT, PET and PET/CT for detection of coronary artery 
disease.  
 
*
NA-not available. 
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Table 2.2 Mean diagnostic value of SPECT, PET and PET/CT for detection of coronary 
artery disease by individual coronary branches.  
 
*
NA-not available, LAD-left anterior descending, LCx-left circumflex, RCA-right coronary 
artery. 
Table 2.3  Mean diagnostic value of nuclear medicine imaging with use of different 
radiotracers.  
 
 
*
NA-not available. 
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Figure 2.3 Pooled diagnostic value of SPECT for detection of coronary artery disease based 
on individual coronary artery assessment. 
 
Figure 2.4 Pooled diagnostic value of PET for detection of coronary artery disease based on 
individual coronary artery assessment. 
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Figure 2.5 Pooled diagnostic value of PET/CT for detection of coronary artery disease based 
on individual coronary artery assessment. 
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Figure 2.6 Pooled diagnostic value of nuclear medicine imaging with use of variable 
radiotracers for detection of coronary artery disease. 
Comparison of SPECT, PET and PET/CT 
 
There is a significant difference in sensitivity, specificity and accuracy between PET and 
SPECT, PET and PET/CT, SPECT and PET/CT for the diagnosis of CAD (p<0.05), with 
PET demonstrating the highest diagnostic value among these three imaging modalities as 
shown in Figure 2.2.  
 
Analysis of diagnostic value for assessment of individual coronary artery disease 
 
Table 2.2 demonstrates the diagnostic value of SPECT, PET and PET/CT in three studies 
with five comparisons based on analysis of three main coronary arteries. Figures 2.3 to 2.5 
demonstrate the overall results of sensitivity, specificity and accuracy analysed with three 
different nuclear medicine modalities at left anterior descending (LAD), left circumflex 
(LCx) and right coronary artery (RCA). As shown in the figures, PET has the highest 
diagnostic value among the 3 imaging modalities for diagnosis of CAD. 
 
Analysis of effects of different Radiotracers on diagnostic value 
 
Since different types of radiotracers were used in these 20 studies, analyses of the diagnostic 
value of variable radiotracers for detection of CAD were investigated. Table 2.3 shows the 
radiotracers used in these studies and their corresponding diagnostic value. As demonstrated 
in the table, using ammonia as a radiotracer produced the highest diagnostic value for 
detection of CAD. Figure 2.6 shows the differences in sensitivity and specificity between 
both 
201
Thallium and 99mTcsestamibi for the diagnosis of CAD (p<0.05), and also 
significant differences in the specificity and accuracy between both 
201
Thallium and 
99
mTc-
sestamibi and individual radiotracers for the diagnosis of CAD (p<0.05).  
 
Significant differences in sensitivity and accuracy was found between 
13
N ammonia, 
82Rubidium and both 
13
N ammonia with 82Rubidium for the diagnosis of CAD (p<0.05) as 
shown in Figure 2.6 Significant differences were found in the sensitivity and specificity 
between use of combined radiotracers (13N ammonia and 
82
Rubidium, 
201
Thallium and 
99
mTc-sestamibi) and use of individual radiotracers alone for the diagnosis of CAD (p<0.05). 
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2.4  Discussion  
 
This systematic review presents three significant findings which are considered to be 
important from a clinical perspective. First, the diagnostic value of SPECT and PET/CT in 
the detection of CAD is moderate when compared to invasive coronary angiography. Second, 
PET has higher sensitivity and specificity than SPECT or PET/CT for detection of CAD, 
indicating the increasing diagnostic accuracy of PET in cardiac imaging. Lastly, there are 
significant differences when different radiotracers are used for the diagnosis of CAD, with 
the use of combined radiotracers resulting in improved diagnostic value. 
 
SPECT has been used as a routine technique in clinical practice for myocardial perfusion 
imaging for decades.
29
 Previous studies have shown that the diagnostic value of SPECT in 
cardiac imaging is variable, ranging from low to moderate.
30
 Di Carli et al.
45
 compared three 
studies using SPECT with PET, looking particularly at the diagnostic accuracy for detection 
of CAD. Only the sensitivity and specificity were provided in their study while the analysis 
of diagnostic accuracy was not identified. This analysis confirms their results to a greater 
extent, as the mean sensitivity, specificity and accuracy of SPECT for detection of CAD are 
moderate.  
 
This indicates that SPECT has not reached the diagnostic accuracy to be considered as a 
reliable technique for assessment of CAD. PET has been used more recently in cardiac 
imaging, and early results look promising.
46
 PET offers potential advantages in a clinical 
practice over myocardial perfusion scintigraphy.
47
 PET is able to assess myocardial blood 
flow and is superior in detecting multivessel disease.
48
 Our analysis identifies PET as having 
the highest diagnostic value for CAD among the three different nuclear imaging modalities 
analysed.  
 
Husmann et al.
26
 compared SPECT and PET in respect to diagnostic accuracy of myocardial 
perfusion imaging. Only the sensitivity and specificity were reported in their study, while the 
diagnostic accuracy was not available. In contrast, the sensitivity, specificity and accuracy of 
PET for detection of CAD were analysed in our report. This review provides a 
comprehensive analysis of the diagnostic value of these nuclear modalities, including 
sensitivity, specificity and accuracy.  
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Thus, it is believed that the analysis offers additional and valuable diagnostic information, as 
compared to the previous reports in the literature. Recently, cardiac imaging has been further 
enhanced by the use of integrated PET/CT, a combined modality which provides the 
considerable benefit of anatomical and physiologic assessment in patients with CAD.
37, 38
  
PET/CT allows precise detection and localisation of CAD.
39
 CT coronary angiography 
provides superior anatomical details but lacks the functional information of cardiac perfusion.  
 
The latest refinements in CT technology, including multidetector CT with faster gantry 
rotations, and dual-source devices, have advanced CT angiography as a promising alternative 
to conventional angiography in the diagnosis of CAD selected patients.
49
  Recent studies have 
shown that 64-slice CTA has high sensitivity (73%- 100%) and specificity (90%-90%) in the 
detection of CAD. 
50-52
 PET offers evidence of sub-clinical coronary atherosclerosis as it is 
superior in demonstrating metabolic activities, but its spatial resolution is limited when 
demonstrating coronary anatomical structures.
48
  
 
Thus, combined PET/CT overcomes the limitations of each individual modality while 
maximising the advantages of both PET and CT in cardiac imaging.
45-47
 However, the 
analysis of integrated PET/CT for detection of CAD was not as good as initially expected 
since PET/CT was shown to have moderate sensitivity, specificity and accuracy. This may be 
due to the selection of patients with different risk factors in the studies analysed. Therefore, 
results of this analysis should be interpreted with caution. PET/CT may show improved 
diagnostic accuracy in other areas, such as tumour imaging, but not in the diagnosis of CAD, 
based on this analysis. 
 
This analysis also involves a comparison of radiotracers used in SPECT and PET imaging 
which includes seven different types of radioisotopes, namely 
201
Thallium, 
99m
Tc-tetrofosmin, 
99m
Tc-Sestamibi, a combination of 
201
Thallium and 
99m
Tc-Sestamibi, 
13
N Ammonia, 
82
Rubidium, and a combination of 
13
N Ammonia and 
82
Rubidium. The comparative analysis 
indicates significant benefits of using 
13
N ammonia for MPI to detect CAD by PET, leading 
to the highest sensitivity and accuracy. Both 
13
N ammonia and 
82
Rubidium have significantly 
high specificity in MPI by PET.  
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PET imaging with use of 13N ammonia, 
82
Rubidium, and a combination of 13N ammonia 
and 
82
Rubidium for diagnosis of CAD, has been found to result in significant differences in 
sensitivity, specificity and accuracy than those using 
201
Thallium, 
99m
Tc-sestamibi, and a 
combination of 
201
Thallium and 
99m
Tc-sestamibi by SPECT imaging.  
 
This is consistent with results reported by other studies. Go and colleagues 
29
 compared PET 
and SPECT in 202 patients. Their results showed there was no significant difference between 
PET imaging with use of 
82
Rubidium and SPECT imaging with 
201
Thallium. Tamaki and 
colleagues 
30
 compared 
13
N ammonia PET with 
201
Thallium SPECT and reported similar 
findings. Hence, this analysis confirms that 13N ammonia PET and 
201
Thallium SPECT 
provide high diagnostic value for detection of CAD. 
 
 In addition, the analysis of individual coronary arteries demonstrates the superiority of PET 
over the other two modalities, but a significant difference in diagnostic value was only found 
between PET and SPECT, PET/CT in LAD. PET/CT was found to be significantly higher 
than PET in the assessment of RCA in terms of diagnostic accuracy. However, only a few 
studies presented the analysis of individual coronary arteries, thus a robust conclusion cannot 
be drawn based on the current analyses. 
 
2.5  Conclusion  
 
This analysis shows that PET has higher sensitivity, specificity and accuracy for detection of 
CAD than SPECT and PET/CT. PET can be used as a reliable, less invasive modality for 
functional analysis of patients suspected of CAD. Further studies comprising a large sample 
size are needed to verify these results. 
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Chapter 3  A head to head comparison of the coronary calcium score by 
computed tomography with myocardial perfusion imaging in predicting 
coronary artery disease 
 
3.1 Introduction  
 
Multi-slice computed tomography (CT) has been increasingly used to detect coronary artery 
calcium and diagnose coronary artery stenosis. Quantifying the amount of coronary artery 
calcium (CAC) with non-enhanced CT scans has been widely accepted as a reliable non-
invasive technique for screening patients with a potential risk of developing major cardiac 
events, and is usually quantified using the Agatston score.
1-4
  The clinical application of CAC 
scoring has been supported by evidence showing that the absence of calcium reliably 
excludes obstructive coronary artery stenosis,
5
 and that the amount of CAC is a strong 
predictor for risk assessment of myocardial infarction and sudden cardiac death, independent 
of conventional coronary risk factors.
6,7
  
However, its predictive value is, in the end, determined by the patients' symptoms. In 
symptomatic patients, CAC scoring is considered as being only marginally related to the 
degree of coronary stenosis, and it is well known that both obstructive and non-obstructive 
coronary artery disease (CAD) can occur in the absence of calcification.
8,9
  According to 
these reports, low CAC scores are less valuable in the prediction of the prevalence, or 
severity, of coronary artery disease caused by the non-calcified coronary plaques. 
Myocardial perfusion imaging (MPI) with gated single photon emission computed 
tomography (SPECT) has been widely used in the diagnosis of CAD and risk stratification 
with high diagnostic accuracy
10,11
 when compared to CT angiography. The presence of 
ischemia could be used to classify the patients as having CAD and candidates for receiving 
aggressive medical therapy and management. However, a normal MPI does not necessarily 
exclude significant coronary stenosis, while high CAC scores sometimes do not result in 
abnormal perfusion on MPI.
12-14
  
Thus, the exact relationship between CAD and MPI is not very clear. The purpose of this 
study is to correlate CAC scores with MPI by SPECT in a group of patients with suspected 
CAD. 
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 An important strength of this study is that simultaneous assessment of MPI and CAC scores 
was performed on all consecutive patients with suspected CAD, thus, the results could be 
applicable to similar populations of patients undergoing MPI examination. 
3.2 Materials and methods  
        Patient data collection 
This retrospective study consisted of 48 patients (33 men and 15 women; mean age 61.7 
years; range 44–81 years) with suspected coronary artery disease that underwent both multi-
slice CT and MPI-SPECT examinations within two weeks. Patients who were referred first 
by general practitioners for coronary CT scans, and then, for MPI-SPECT by nuclear 
physicians, met the following inclusion criteria: no previous history of CAD; typical or 
atypical chest pain, dyspnea or signs of myocardial perfusion on a resting or stress ECG test.  
Medical history, including cardiovascular risk factors, blood pressure, lipid profile, 
electrocardiography (ECG) and 10-year CAD risk, predicted on the basis of the Framingham 
risk score, was obtained for all patients (pretest probability: low to moderate).  
Patients were excluded if they had a previous history of myocardial infarction, unstable 
angina, percutaneous coronary intervention (angioplasty) or coronary bypass surgery; allergy 
to contrast medium and renal insufficiency (serum creatinine > 1.5 mg/dL). All patients were 
in a stable condition at the time of the study. The study was approved by the local ethics 
research committee and written informed consent was obtained from all patients. The 
characteristics of the study population are summarised in table 3.1. 
Table 3.1 Patient demographics. 
Males  33 (69%) 
Females  15 (31%) 
Age (years, mean ± SD)  61.7 (9.8) 
Cardiovascular risk factors 
Smoking  13 (27%) 
Hypertension  41 (83%) 
Diabetes  8 (17%) 
Dyslipidemia  13 (27%) 
Angina pectoris 
Atypical  7 (14.6) 
Typical  41 (85.4%) 
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       Coronary CT scanning protocol 
 
All patients were scanned on a dual-source CT scanner (Somatom Definition, Siemens 
Medical Solutions, Forchheim, Germany). A non-enhanced scan was performed for CAC 
scoring. Scanning parameters were as follows: detector collimation 2 × 32 × 0.6 mm, slice 
collimation 2 × 64 × 0.6 mm by means of a z-flying focal spot, gantry rotation time 330 ms, 
pitch of 0.2–0.5 depending on the heart rate, tube current time product 350 mAs and tube 
potential 120 kV.  
CT scans were performed from the level of the tracheal bifurcation to the diaphragm. Non-
enhanced CT scans were performed with prospective ECG-triggering with images acquired at 
three mm slice thickness. 
 
      Coronary artery calcium scoring 
 
Coronary artery calcifications were quantified using calcium scoring software (Syngo 
CaScore, Siemens) and measurments were performed by a qualified CT technologist using 
the standard Agatston calcium scoring algorithm.
4
 The extent of CAD was determined 
according to the recommended CT calcium score guidelines using five CAC score categories: 
none (0), minimal or low (1–10), mild (11–100), moderate (101–400) and extensive or high 
(401 or greater). 
     MPI-SPECT imaging protocol 
 
Rest and stress ECG-gated MPI protocols were performed in all patients using technetium 
(
99m
Tc)-tetrofosmin (500 MBq). The stress test was performed on an exercise-modified Bruce 
treadmill and associated (such as adenosine infusion) protocol. Images were acquired on a 
triple-head SPECT camera (ADAC Vertex with VXGP collimators) using a low-energy, 
high-resolution, parallel-hole collimator with a 360 rotation in a continuous mode. All 
projection images were stored in a 64 × 64 × 16 acquisition and processing frame matrix size. 
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     MPI-SPECT image analysis 
The myocardial perfusion assessment was performed by a nuclear physician with more than 
10 years of experience in nuclear cardiology using a 20-segment model, and myocardial 
perfusion for each segment was evaluated using a five-point continuous scoring system as 
recommended by Xu et al.
15
 (0: normal; 1: mildly abnormal; 2: moderately abnormal; 3: 
severely abnormal; 4: absence of segmental uptake). The observer was blinded to any clinical 
information and CAC scores.  
The segmental perfusion scores during rest and stress were added to calculate the summed 
rest score (SRS) and the summed stress score (SSS). The summed difference score (SDS) 
was calculated by subtracting the SRS from the SSS. 
 
      Statistical analysis 
Data were entered into SPSS V 19.0 for analysis (SPSS, Chicago, Illinois). All continuous 
variables were expressed as mean ± SD. A one way analysis of variance (ANOVA) was used 
for analysis of continuous variables and a Pearson test was used to demonstrate the 
correlation between CAC and MPI scores. A P value of less than 0.05 indicated statistically 
significant difference. 
3.3 Results  
 
Table 3.2 lists the CAC and MPI-SPECT scores as assessed in these patients. There are 
variable degrees of differences between the CAC and corresponding MPI-SPECT scores. 
Figure 3.1 shows the distribution of CAC and MPI scores among these 48 patients. Forty-
seven percent of the patients had moderate and extensive calcifications with CAC scores 
more than 100, while 42% of these patients demonstrated abnormal, or probably abnormal, 
MPI assessments. Analysis of the relationship between overall CAC scores and MPI 
assessments indicated no correlation with a Pearson correlation factor r of 0.019 (Figure 3.2). 
Table 3.2. Percentages of coronary artery calcium score and MPI-SPECT results. 
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CAC: coronary artery calcium; MPI: myocardial perfusion imaging. 
 
Figure 3.1. Distribution of the CAC scores with myocardial perfusion imaging among the 48 
patients with suspected coronary artery disease. 
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Figure 3.2. Graph shows that there is a lack of correlation between coronary artery calcium 
scores and the corresponding myocardial perfusion SPECT assessments, with r value of 
0.019. 
 
A zero CAC score was found in 25% of the patients; however, only 6% of these were noted 
to demonstrate the normal MPI-SPECT results. Of 10 patients with a zero CAC score, 
abnormal MPI-SPECT scores were found to range from 1 to 4 (mean score 2.6). In contrast, 
normal MPI-SPECT scores were found in two patients with a CAC score of four. A CAC 
score of 1–10 was identified in 6% of the patients with probably normal MPI-SPECT 
findings in 17% of the patients. A CAC score of 11–100 was found in 21% of patients with 
equivocal MPI-SPECT findings in 33% of the patients. A CAC score of the 101–400 was 
reported in 23% of the patients with probably abnormal MPI-SPECT findings in 15% of these 
patients. Similarly, there was no correlation between the CAC scores and MPI assessments in 
the group of patients with low to moderate calcification, with a Pearson correlation factor r of 
0.012. 
Extensive calcifications (CAC score > 400) were noticed in 25% patients, while 29% of 
patients were found to have abnormal MPI. Again, there was no correlation between the CAC 
scores and MPI assessments in the group of patients with extensive calcification, with a 
Pearson correlation factor r of 0.080. 
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3.4 Discussion  
 
Although based on a relatively small sample size, this study presents important findings 
which are considered valuable for the clinical diagnosis of patients with suspected coronary 
artery disease. There is a lack of correlation between the CAC scores and MPI-SPECT 
assessments, with a significant difference observed between these scoring techniques, 
especially in the patients with zero or mild calcification (CAC scores 0–100). Thus, CAC 
scores cannot be reliably used as single parameters to predict the disease prognosis in this 
group of patients. 
CAC score using multi-slice CT has been validated as a useful imaging tool for risk 
stratification and reclassification of risk of coronary artery disease.
16
  The CAC score is a 
highly sensitive marker with increased prognostic value for determining the atherosclerotic 
disease compared with conventional cardiovascular risk factors. However, issues have been 
raised as to whether using only a CAC score is a reliable tool of determining the extent of 
CAD, since non-calcified coronary artery plaque may not be detected.  
There is growing evidence to show the discrepancy between low CAC and corresponding 
myocardial perfusion findings.
8,17,18
 This is confirmed by the results in this analysis as there 
is no correlation between the CAC scores and MPI assessments, whether the analysis is based 
on a comparison of overall CAC scores and MPI assessments, or on low or high CAC scores 
with corresponding MPI assessments. 
Several studies have reported the presence of obstructive non-calcified plaque in 8.7% of 
symptomatic patients with zero or low calcium scores.
8,17
 Cheng et al.
17
  reported that low, 
but detectable, CAC scores were less reliable in predicting the plaque burden due to their 
association with high overall non-calcified coronary artery plaque. Similarly, Greenland, et 
al.
18
 demonstrated a CAC of zero did not usually eliminate the risk of future CAD events. 
Our results are in line with those findings. Twenty-three percent patients had a zero CAC 
score with only 7% of these patients verified by the myocardial perfusion SPECT to be 
normal. It could be concluded that low CAC scores are significantly less predictive of the 
prevalence, or severity, of underlying non-calcified coronary plaque,
19
 although further 
studies based on a larger cohort of patients should be conducted. 
81 
 
It has been reported that the MPI-SPECT in cardiac imaging is a widely accepted test for the 
diagnostic and prognostic evaluation of patients with known, or suspected, CAD.
10,20
 This 
study indicates that MPI-SPECT may provide more accurate assessments of the extent of 
CAD, or the prediction of disease outcomes, than CAC alone, given that, in patients with zero 
CAC, some could demonstrate abnormal myocardial perfusion. Schaap, et al.
21
 in their recent 
study concluded that a CAC score did not significantly improve the diagnostic performance 
of SPECT in patients with significant CAD. The association between CAC and MPI-SPECT 
demonstrates that as the CAC score increases, so does the occurrence and severity of 
myocardial perfusion abnormalities.
22,23
   
High values of CAC often indicate the presence of stenotic lesions and are associated with an 
increased risk of adverse cardiovascular events.
16,24,25
 Similarly, our study shows that patients 
with a high calcium score had abnormal, or probably abnormal, MPI-SPECT results, 
although the correlation between these imaging modalities was not significant. However, 
studies have been reported that patients with a high CAC score did not demonstrate a 
significantly different percentage of abnormal MPI findings than in patients with a low CAC 
score.
12,14
   
A high CAC in patients with normal MPI-SPECT reflects non-obstructive atherosclerosis, 
which is regarded as a preclinical state with strong predictive value for the development of 
CAD, thus, aggressive risk factor modification should be recommended according to the 
guidelines.
26
 A CAC score and MPI should be considered complementary approaches rather 
than individual parameters in the assessment of patients with suspected CAD. 
Several limitations in this study should, however, be acknowledged. Firstly, only a limited 
number of patients were included in this study and further studies based on a larger cohort are 
needed.  
Secondly, this study is only a retrospective analysis of the diagnostic reports without the 
inclusion of follow-up details on patients, thus, there is no information available about the 
disease outcomes, such as major cardiac events relative to the CAC or MPI scores.  
Thirdly, the cut off value for CAC at 401 or greater in this study is much lower than the 
suggested value in the literature (> 700),
27,28
  thus, this could affect the diagnostic specificity 
in detecting significant CAD.  
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Lastly, the diagnostic accuracy of coronary CT angiography was not assessed with regard to 
the evaluation of the degree of coronary stenosis, with no correlation to subsequent 
myocardial perfusion analysis, thus, no information is available about the diagnostic value in 
terms of sensitivity and specificity.  
This could be explained by the fact that the current study only focused on the correlation 
between CAC and MPI-SPECT. Recent evidence shows that coronary calcium scores 
assessed with non-enhanced CT might be supported by coronary CT angiography or coronary 
CT angiography might be performed alone with the aim of acquiring more diagnostic 
information.
29,30
  Further studies are required to investigate the potential value of coronary 
CT angiography for both calcium scoring and assessment of coronary stenosis. 
In conclusion, this study demonstrates the lack of direct correlation between the CAC score 
and the corresponding myocardial perfusion assessed by SPECT in patients with suspected 
coronary artery disease. In particular, in patients with a zero or low CAC scores, myocardial 
perfusion imaging shows potential abnormalities in some patients which indicate significant 
lack of agreement between these two methods.  
This highlights the limitations in using CAC scores alone as a predictor of coronary disease 
outcomes. Coronary calcium score should be combined with myocardial perfusion imaging in 
low-to-intermediate risk patients to improve the diagnostic performance. 
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Chapter 4  Myocardial Perfusion Imaging Using 99mTc-MIBI Single 
Photon Emission Computed Tomography: A Cardiac Phantom Study 
 
4.1 Introduction  
 
Ischemic heart disease continues to be the most common aetiology for myocardial infarction 
in developed countries.
1,2
  Medical imaging modalities have undergone rapid developments 
over the last decade, such as multislice CT, magnetic resonance imaging and radionuclide 
imaging with excellent visualisation of anatomical structures and functional assessment of 
cardiac disease.
3-9
  
 
Of these imaging techniques, myocardial perfusion single photon emission computed 
tomography (SPECT) has been established as a non-invasive method for the diagnosis of 
coronary artery disease with flow-limiting lesions with a sensitivity and specificity of 87–
89% and 73–75%, respectively, depending on the selection of radioisotope and stress 
modality.
10
  
 
Furthermore, SPECT has been reported to be a valuable diagnostic modality for risk 
stratification with a normal perfusion scan being associated with very low risk of death or 
non-fatal myocardial infarction.
10
 SPECT myocardial perfusion imaging performed with 
Technetium-99 (
99M
Tc)-based radiopharmaceuticals is widely used in daily clinical practice 
for diagnosing coronary artery disease and stratifying patients according to cardiac risk 
factors.
11,12
  
 
Despite these advantages, myocardial perfusion SPECT has been challenged by the 
emergence of positron emission tomography (PET) as PET has higher spatial and temporal 
resolution than SPECT, which allows more accurate quantification of regional myocardial 
perfusion.
13-15
 However, both SPECT and PET suffer from radiation exposure to patients, 
thus, selection of protocols for individual patients is essential to ensure the implementation of 
an ―as low as reasonably achievable‖ approach.16   
 
The purpose of this study was to develop a cardiac phantom and test SPECT myocardial 
perfusion imaging using 
99m
Tc-MIBI under normal and simulated conditions in the left 
ventricle.  
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It is expected that this preliminary study will lay the foundation for further experiments on 
the cardiac imaging comparing SPECT with PET with regard to minimizing radiation dose of 
myocardial perfusion protocols. 
 
4.2 Materials and methods  
Phantom Design and Experimental Setup  
 
A realistic thorax-heart phantom was designed to serve as purpose of performing myocardial 
perfusion imaging. The phantom consists of left ventricle, right ventricle, vertebral column 
and lungs (Fig. 4.1). The phantom was made from Perspex and Acrylic materials with two 
cylinders consisting of a half-spherical end and inner cylinder which forms the ventricular 
chambers. The space between two cylinders represents the myocardial wall chamber. The left 
and right ventricles were located between the lung cavities (Fig. 4.2).  
 
The defects which were made from solid inserts caused cold spot which represents 
myocardial perfusion defects (Fig. 4.3). Sponges were used to support the position of heart 
phantom in an angle of about 45◦ which is similar to the normal heart position within the 
chest (Fig. 4.4). 
 
 
Figure 4.1. Diagrams show the anatomical structures of cardiac phantom consisting of left 
and right ventricles. (A) lateral view, (B) superior view. 
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Figure 4.2. Diagrams show the phantom position in relation to the chest wall and lungs. 
 
 
(A)  (B) 
Figure 4.3. External views of cardiac phantom showing the simulated infarcted areas at 
different locations of the left ventricular wall (blue solid areas). 
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(A)  (B) 
Figure 4.4. Cardiac phantom with water and radioisotope filled in the left ventricular wall and 
positioned in an angle similar to the normal heart position within the chest. (A) lateral view, 
(B) superior view. 
 
SPECT Image Acquisition 
 
All phantom image acquisitions were performed on a three-head SPECT/CT camera (IRIX 
300D, Philips) with low-energy collimator at 140 keV. A rest myocardial perfusion imaging 
protocol without ECG-gating was performed in the phantom. A step-and-shoot mode was 
used for SPECT acquisition, with a 64×64 acquisition and processing frame matrix size and 
zoom of 1.49. The time per frame was 30 sec.  
 
SPECT data were processed using standard reconstruction software based on a filtered back 
projection method. The CT images were used to provide attenuation factors for correction of 
the SPECT data. Phantom acquisitions were single-isotope studies with injection of a small 
amount of radioisotope of 0.6 mCi of 
99m
Tc sestamibi mixed with 160 ml of water into the 
left ventricular wall to simulate myocardial perfusion.  
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Simulated infarcts were located in the anterior and septal regions of the left ventricular wall 
to produce moderate and severe defects. 
 
4.3 Results  
 
Cardiac SPECT imaging was successfully performed on the phantom with demonstration of 
both normal myocardium and ischemic defects due to presence of simulated infarction. 
Figure 4.5 (A) shows circumferential profiles of the short-axis and long-axis (vertical and 
horizontal) slices of normal myocardium, while Figure 4.6 (A) demonstrates the severity of 
the inserts from the 
99m
Tc SPECT study.  
 
The simulated infarcted areas were clearly visualised on both axes in the left ventricular wall. 
Using a simple 20-segment polar map, all tomographic slices of the myocardium under both 
normal and infarcted conditions (Figs. 4.5 (B) and 4.6 (B) were shown with similar 
appearance to that observed on the short and long-axis slices.  
 
The ischemic change due to simulated moderate and severe infarcted lesions was 
demonstrated at the anterolateral and apical anteroseptal segments, which are shown in 
Figure 4.6 (B). 
 
                                                                        (A) 
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                                                             (B) 
Figure 4.5. Rest cardiac SPECT imaging of normal myocardium. (A) is short and long axis 
view of the left ventricular myocardium, while (B) refers to the 20-segment polar map views. 
 
 
                                                                       (A) 
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                                                                      (B) 
Figure 4.6. Rest cardiac SPECT imaging of abnormal myocardium. (A) shows the ischemic 
changes in the left ventricular myocardium visualised on the short and long axis, while (B) 
refers to the 20-segment polar map views of the corresponding infarcted areas. Arrows point 
to the infarcted areas. 
 
4.4 Discussion  
 
This study shows our preliminary experience of testing myocardial perfusion SPECT imaging 
on a cardiac phantom during normal myocardium and simulated infarction. Results show the 
feasibility of demonstrating cold lesions created by the inserts. Over the last two decades, 
SPECT myocardial perfusion imaging has become an imaging modality in the routine 
management of patients with suspected or known coronary artery disease.
11
  
 
Thallium-201 (
201
T1) SPECT is the oldest and most common method of assessing myocardial 
ischemia. It is also a well-established means of measuring myocardial viability. Nonetheless, 
99m
Tc-based radiopharmaceuticals (sestamibi and tetrofosmin) have become the dominant 
perfusion tracers of SPECT myocardial perfusion imaging in daily clinical practice, due in 
part to the higher count rates of the 
99m
Tc agents.
17,18
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This is confirmed in this study as simulated infarcted lesions are reliably detected on SPECT 
images using the radioisotope of sestamibi. Although advances in cardiac imaging procedures 
have improved the ability to assess and treat cardiovascular disease, radiation dose is 
becoming a major issue since cumulative radiation exposure from general medical imaging is 
substantial in many individuals.  
 
Myocardial perfusion imaging has been reported to account for more than 22% of total 
effective dose of radiation received by the study population consisting of 655, 613 subjects 
who underwent at least one imaging procedure associated with radiation dose.
19
 CT and 
nuclear imaging accounted for 21% of the total number of procedures and 75.4% of the total 
effective dose, according to Fazel et al.’s study.19  
 
Extensive research has been performed in cardiac CT imaging with successful dose reduction 
being achieved by incorporating optimal techniques,
20-22
 however, there is a lack of patient-
level data on radiation exposure from cardiac nuclear imaging procedures despite a rapid 
increase in their use. We believe the cardiac phantom developed in this study can be used to 
investigate optimal SPECT and PET protocols with the aim of reducing radiation exposure to 
patients. 
 
The effective doses for most of the radiopharmaceuticals used in myocardial imaging are 
between 2–15 mSv per study, with the highest dose being reported in SPECT using 201T1 
which may reach up to 20–30 mSv, and the lowest values being noted for 13N–NH3 and 15O 
studies.
23
  
 
The doses per study for 
99m
Tc and 
201
T1-labeled radionuclides differed significantly by about 
a factor of 2, and this difference must be evaluated in the context of the numeric uncertainty 
in individual values. The average amount of radiopharmaceutical used in a resting 
99m
Tc-
MIBI study is 20 mCi, with an effective dose of 6.7 mSv.
24
 In this study, only 0.6 mCi was 
used in the SPECT imaging, which is equivalent to 0.2 mSv.  
 
Further studies based on different volumes of radiopharmaceuticals should be conducted to 
confirm the diagnostic image quality of SPECT myocardial perfusion imaging with resultant 
low radiation dose. 
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There are some limitations in this study that should be acknowledged. First, although the 
phantom represents normal anatomic structures, it does not have the movable function of 
heart beats; thus, stress SPECT imaging could not be conducted.  
 
Second, this experimental study only tested the feasibility of SPECT imaging on the cardiac 
phantom, without measuring the image quality, such as contrast values on both normal 
myocardium and infarction areas or diagnostic value in terms of sensitivity and specificity. 
This can be explained by the reason that this preliminary study only focused on testing of the 
phantom design and clinical applicability. 
 
Further experiments are needed to investigate the quantitative assessment of image quality 
and qualitative analysis of the detection of inserts. Third, although CT images were used for 
attenuation correction, the cardiac phantom was not tested inside the thoracic cavity, 
therefore, no attenuation from chest wall such as breast tissue or thick chest wall was 
available in the experiments. Further studies with cardiac phantom placed in the realistic 
chest wall are needed as this is especially important because the experiments were used to 
test low-dose protocol, while low-dose protocol will suffer from chest wall attenuation to a 
greater extent which could potentially lead to false positive results.  
 
Finally, this study was performed on a SPECT camera, while PET has been recently reported 
to be superior to SPECT in myocardial perfusion imaging due to its high spatial and temporal 
resolution.
13-15, 24,25
 Comparison of myocardial perfusion imaging with SPECT and PET is 
suggested in further experiments with the aim of determining the diagnostic value of SPECT 
compared to PET.  
 
In conclusion, we have developed a cardiac phantom with insertion of infarcted areas in the 
left ventricular wall, and tested SPECT myocardial perfusion imaging. Both normal 
myocardium and simulated infarcted areas are clearly visualised on SPECT images. The 
phantom can be used to conduct further experiments, including comparison of SPECT with 
PET using different isotopes, and investigation of optimal cardiac protocols for radiation dose 
reduction while achieving diagnostic images. 
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Chapter 5 Diagnostic value of 18FDG PET in myocardial viability in 
comparison with 
99m
Tc SPECT and echocardiography 
 
 
5.1 Introduction 
Coronary artery disease (CAD) is the most common cause of cardiovascular disease 
responsible for inducing heart attack. Assessment of myocardial viability is an important 
approach to determine the myocardial function therefore, assisting effective patient 
management to reduce the mortality. Assessment of myocardial viability is regarded as an 
appropriate diagnostic technique after revascularisation in patients with damaged left 
ventricle (LV) function and indication of myocardial viability.
1-5
  
The viability can be described as living myocardium. The clinician is concerned about 
determining whether dysfunctional myocardium is alive or deceased. Viable myocardium 
refers to areas that can be stunned or hibernated. LV dysfunction may be permanent if a 
myocardial scar is found, or it may be reversible after revascularization. Reversible LV 
dysfunction occurs when the myocardium is viable but dysfunction. Since only patients with 
dysfunctional but viable myocardium benefit from revascularization, the identification and 
quantification of the extent of myocardial viability is an important part of the work-up of 
patients with CAD or heart failure when determining the most appropriate treatment strategy. 
Metabolically depressed ruling of myocardium in response to a concentrated state of 
myocardial perfusion refers to hibernation. 
6,7
 
There are a number of diagnostic techniques used to classify myocardial viability such as 
single photon emission computed tomography (SPECT), positron emission tomography 
(PET), cardiac magnetic resonance imaging (MRI).  Myocardial SPECT technique is widely 
used with different radioisotopes, such as thallium-201 (
201
TI) and technetium-99m (
99m
Tc).  
Myocardial PET has been also used with fluorine-18-fluorodexy glucose (
18
F-FDG) as a 
routine procedure in clinical centres. Presently, 
18
F-FDG PET imaging is considered as the 
gold standard for the diagnosis of myocardial viability. 
8-10 
 
Studies have shown that cardiac SPECT and PET have high diagnostic performance in the 
assessment of myocardial viability 
11-13 
with high sensitivity, specificity and accuracy in 
patients after revascularisation.  
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Also, it has been suggested that the use of nuclear medicine techniques for myocardial 
viability prediction improved survival after coronary artery bypass grafting.   
14-25
  
Despite these promising results, there is still a lack of scientific data with regard to the 
diagnostic value of cardiac PET in the evaluation of myocardial perfusion when compared to 
SPECT or other functional imaging modalities. Thus, the purpose of this study is to 
investigate the diagnostic value of 
18
F-FDG PET in the assessment of myocardial viability 
patients with known coronary artery disease when compares to the routinely performed 
99m
Tc-tetrofosmin SPECT and echocardiography by using invasive coronary angiography as 
the gold standard. We hypothesized that 
18
F-FDG PET has the ability to demonstrate high 
diagnostic accuracy in the detection of myocardial viability. 
 
5.2 Materials and Methods 
5.2.1 Study population 
This prospective study involved consecutive recruitment of patients with known or proved 
coronary artery disease who underwent invasive coronary angiography and echocardiography 
in National Heart Institute, Malaysia and Universiti Kebangsaan Malaysia Medical Centre. 
All patients had previous history of myocardial infarction and LV dysfunction. Exclusion 
criteria included patients with suspected CAD but clinically confirmed or non-ischemic LV 
dysfunction, patients refused to participate in the study and patients with pregnancy. Thirty 
patients met the selection criteria, however, only ten patients (9 men; mean age 59.5 ± 10.5 
years) agreed to participate in the study and eventually underwent all of these imaging 
procedures consisting of invasive angiography, echocardiography, SPECT and PET. All 
patients signed consent forms, and ethical approval was obtained from each institutional 
review board. 
5.2.2 Imaging protocols-invasive coronary angiography 
Coronary angiography was carried out using the standard Seldinger’s technique on an 
angiographic machine by femoral approach which was performed by cardiologists at the 
National Heart Institute.  Cardiologists who had no prior knowledge of SPECT or PET 
findings quantitatively analyzed the severity of coronary stenosis. The minimal lumen 
diameter was measured in projections showing the most severe narrowing. 
99 
 
 
5.2.3 Echocardiography protocol 
Dobutamine echocardiography was performed using a standard protocol. First, resting 
echocardiography was achieved with the patient placed in the left lateral leaning position. 
Echocardiographic imaging was then completed through an intravenous infusion of 
dobutamine, first at a dose of 5 μg/kg/min, then it was increased at every 3 min to 7.5, 10, 20, 
30, and 40 μg/kg/min, respectively. Images were acquired in the normal parasternal long-axis 
and short-axis views, with particular attention paid to determining the regional cardiac 
function. Through dobutamine infusion, the 12-lead ECG and blood pressure were observed 
every minute. The test was completed early if the heart rate extended 85% of the predicted 
maximum. 
5.2.4 Cardiac SPECT protocol  
All patients underwent a gated-SPECT 
99m
Tc tetrofosmin (GE VENTRI). After a minimum of 
4 hours of fasting, nitrates were stopped for 12 hours prior to the study. After intravenous 
cannulation, 
99m
 Tc tetrofosmin 450 MBq (12 mCi) was administered intravenously under 
resting conditions. About 45-60 minutes after radiotracer injection, a resting SPECT study 
was performed under double-headed gamma camera equipped with high-resolution 
collimators. Data were acquired in 64x64 matrix, with 32 projections, and 8 frames per 
cardiac cycle, and were used in association with a 20% window centred on the 140-keV 
photon peak of 
99m
Tc. 
All data from the 
99m
Tc-tetrofosmin SPECT studies were reoriented into short-axis and 
horizontal and vertical long-axis sections. Quantitative analysis was performed using a 
commercially available gated-cardiac software package (4D-MSPECT; University of 
Michigan Medical Center) for assessing LV regional wall motion. 
7
 The LV wall motion was 
classified visually into 4 categories (0= normal, 1 =mild hypokinesis, 2= hypokinesis 
moderate sever   3 = akinesia or dyskinesia) using a 17-segment model (4 basal and distal 
segments [anterior, lateral, septal, and inferior] and 1 apical segment). 
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5.2.5 Cardiac PET protocol 
All the patients were informed to fast for at least 6 hours before the scan and baseline blood 
sugar was checked. About 45-60 minutes after the 50-75 g of injected glucose loading, blood 
sugar was checked. If it was <140 mg/dL, 444 MBq (12 mCi) of 
18
F-FDG was injected 
intravenously. If it was >140 mg/dL, regular insulin was injected intravenously according to 
blood glucose level (2, 3, and 5 U of regular insulin for 140-160, 160-180, and 180-200 
mg/dL of blood glucose, respectively). About 45–60 minutes after FDG injection myocardial 
FDG PET study was performed in a PET scanner in a 3D mode (Siemens Medical Systems, 
Erlangen, Germany). PET acquisition parameters were as follows: myocardium was covered 
in one bed position (5 minute per bed position) with ECG gating (8 frames/RR cycle). 
 
5.2.6 Image analysis 
5.2.6.1 Analysis of echocardiographic images  
Calculations of the regional wall motion were assumed off line using  16- segment model 
according to the American Society of Echocardiography.
26-29
 These 16 segments were 
classified as 0, normal; 1, hypokinetic; 2, akinetic; and 3, dyskinetic.  Only segments within 
the infarction-related coronary segment were analysed for wall motion. From this territory, 
the regional wall motion score was calculated. 
5.2.6.2 Analysis of angiographic images 
The degree of stenosis was classified into four categories: (1) no stenosis, (2) minimal or mild 
stenosis (≤50%), (3) moderate stenosis (50%–70%), and (4) severe stenosis (>70%). CAD 
was defined when lumen diameter reduction was greater than 50% (moderate or severe 
stenosis). 
 
5.2.6.3 Analysis of SPECT and PET images 
A 17-segment model was used for SPECT and PET image analysis.  Each segment in both 
99m
Tc tetrofosmin SPECT and 
18
F-FDG PET
 
was analysed by an automatic method for 
percentage of maximum tracer uptake. Segment performance with 50% of the maximum 
amount was measured as viable as well as for the post-nitrate 
99m
Tc tetrofosmin study.  
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In addition to the qualitative assessment, the ACC/AHA/ASNC guidelines recommend a 
semi-quantitative analysis of PET studies based on a validated segmental scoring system. 
29,30
 
A 17-segment model analysis is proposed using a 5-point scale system in direct proportion to 
the observed count density of the segment: normal perfusion=0, mild defect=1, moderate 
defect=2, severe defect=3 and absent uptake=4. Calculations of the summed scores can also 
be performed incorporating the total extent and severity of a perfusion abnormality.  
 
5.2.6.4 Qualitative SPECT, PET and Echocardiography assessment   
The data were analysed by two radiologists blindly and independently. Both radiologists used 
a 17-segment model to analyse myocardial viability as observed on SPECT and PET images 
and analysis was recommended using a 5-point scale system in through quantity to the 
experimental total density of the segment of left anterior descending (LAD), right coronary 
artery (RCA) and left circumflex (LCX): normal perfusion=0, mild defect=1, moderate 
defect=2, severe defect=3 and absent uptake=4. For echocardiography, the assessment used 
was according to the 16-segments model of the American Society of Echocardiography. 
 
5.2.7 Statistical analysis  
All data were entered into SPSS V 20.0 for statistical analysis (SPSS, Chicago, ILL). 
Continuous variables were expressed as mean ± standard deviation (SD), while categorical 
variables were presented as percentage. A p value of less than <0.05 was considered 
statistically significant difference.  
Agreement in qualitative measurements between radiologists (both intra- and inter-observer 
variability) and between different methods was compared using kappa statistics (κ) and 
classified as follows: poor (κ=0.20); fair (κ=0.21–0.40); moderate (κ=0.41–0.60); good 
(κ=0.61–0.80) and excellent agreement (κ=0.81–1.00). Echocardiography, 99m Tc tetrofosmin 
SPECT, 
18
FDG PET and echocardiography were calculated for diagnostic value when 
compared to invasive angiography which was regarded as the gold standard. 
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5.3 Results   
A total of 10 patients were included in this study and patient’s characteristics are shown in 
Table 5.1. The mean age of the patients were 59.5 (± 10.5) years and the most of patients 
(90%) were males All the patients had proven CAD but the principal diagnosis in 30% of the 
patients had triple vessel disease involving LAD, LCx and RCA with more than ≥50% 
stenosis. 
Table 5.1. Patient characteristics. 
All patients                                                                                          N= 10                                                             
Age (years)                                                                                         59.5 ± 10.5 
Men/women                                                                                                9/1  
Principal Diagnosis (%) 
    Ischaemic Heart Disease                                       10% 
    Ischemic Dilated Cardiomyopathy                  20% 
    Inferior STEMI Thrombolysed                               20% 
    Triple vessel                                                                          30 %                                     
    Non-ST segment elevation myocardial infarction                             10%  
    Double vessel                                                                                        10% 
Cardiac risk factors  
   Diabetes                                                                                                   40% 
  Hypertension                                                                                            80% 
  Smoker                                                                                                     20% 
  Dyslipidaemia                                                                                          30% 
  Obesity                                                                                                     10% 
Patient management 
  Control risk factors                                                            50%  
  Referral for CABG                                               50%   
  Percutaneous Coronary Intervention                  20% 
  Implantable Cardioverter Defibrillator                     10% 
  Medical Therapy                                               10% 
  International Normalised Ratio                                                                20%   
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STEMI-ST elevated myocardial infarction, CABG-coronary artery bypass grafts 
 
5.3.1 Comparison of diagnostic value between SPECT, PET and Echocardiography  
A total of 340 segments in 10 patients were analysed for SPECT and PET imaging 
examinations, while for echocardiography there were 160 segments that were analysed in 
comparison with SPECT and PET. The diagnostic sensitivity of PET, SPECT and 
echocardiography was 100%, 90%, and 80% respectively, as shown in Figure 5.1 Since all 
patients had coronary artery disease, no sensitivity was analysed (true negative value was 
zero). 
 
Figure 5.1. Diagnostic sensitivity among PET, SPECT and Echocardiography in comparison 
with invasive coronary angiography. 
 
5.3.2 Comparison between SPECT and PET for assessment of LAD, LCx, RCA 
Comparison was also performed between PET and SPECT in the assessment of three main 
coronary artery branches, as shown in Figure 5.2. Results showed that PET has the highest 
diagnostic value in the assessment of all of the three main coronary arteries, while SPECT 
has moderate diagnostic value in LAD, but low diagnostic performance in the other two 
arteries, RCA and LCx. 
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Figure 5.2. Comparison between SPECT LAD, LCx, RCA and, PET LAD, LCx and RCA. 
 
5.3.3 Qualitative assessment of SPECT and PET between observers 
Table 5.2 shows the results of inter-observer assessment, namely SPECTobserver 1, 
SPECTobserver 2, PET observer1 and PET observer 2 in the diagnostic evaluation of myocardial 
viability. As shown in the table, PET observer1 has high diagnostic value, while the diagnostic 
performance of PET observer 2 is the same as SPECTobserver 1, SPECTobserver 2, although this did 
not reach significant difference.  Results showed excellent agreement on sensitivity of PET 
observer 1 and PET observer2 with kappa value of 0.9, SPECTobserver 1 and SPECTobserver 2 with kappa 
value of 0.9. 
Table 5.2. Inter-observer assessment between these imaging modalities 
PET/SPECT observer agreement Sensitivity 
PET observer1 100% 
PET observer 2 90% 
SPECTobserver 1 90% 
SPECTobserver 2 90% 
 
Figure 5.3 is an example of SPECT imaging in a patient diagnosed with significant CAD, 
while Figure 5.4 is another example of PET imaging in the same patient with CAD. Both 
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SPECT and PET detected myocardial abnormal changes, although PET is superior to SPECT 
in terms of image quality and accurate assessment of overall all segments. 
 
Figure 5.3. The gated SPECT 
99m
T-tetrofosmin viability study images show marked reduced 
myocardial thickening and akinetic wall motion at the apex, anterior apical, anteroseptal mid 
and inferior mid segments. 
 
Figure 5.4. The gated PET
 18
FDG viability study images show severely reduced 
18
FDG 
uptake in the inferior apical, inferior mid and inferior basal segments. 
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5.4 Discussion  
This prospective study investigates the diagnostic value of non-invasive cardiac modalities 
through comparing 
18
F-FDG PET with 
99m
Tc tetrofosmin SPECT and  echocardiography with 
the aim of determining myocardial viability in patients with known CAD with invasive 
coronary angiography as the gold standard. Our results showed that cardiac PET has a 
sensitivity of 100% and 90% in patients with CAD, which is higher than that of SPECT or 
echocardiography. The assessment of myocardial viability with 
18
F-FDG PET is based on its 
ability to distinguish the two main pathogenic mechanisms for chronic myocardial 
dysfunction in ischemic cardiomyopathy:  
i. Irreversible loss of myocardium due to prior myocardial infarction 
(scar)  
ii.  At least partially reversible loss of contractility owing to chronic or 
repetitive ischemia (hibernating myocardium) .
31
  
The distinctive feature of these two mechanisms is that revascularisation has the potential to 
restore contractile function of the hibernating myocardium but not scar. 
29
 
This distinction may be of paramount importance in clinical decision-making because of the 
upfront morbidity and mortality associated with revascularisation procedures in patients with 
severe left ventricular dysfunction. 
Cardiac PET utilizing 
18
F-FDG is considered the most sensitive modality for detecting 
hibernating viable myocardium and predicting left ventricular functional recovery post-
coronary revascularization. 
32-35
 
18
F-FDG PET imaging showed incremental benefit over 
201
T1 stress-redistribution/reinjection or 
99m
Tc-sestamibi SPECT in predicting functional 
recovery in the patients with very impaired left ventricular function, while in patients with 
relatively preserved left ventricular function, the predictive value was similar. 
36, 37 
 Tillisch et 
al 
29
 in their first landmark trial reported the value of 
18
F-FDG PET to predict reversibility of 
cardiac wall motion abnormalities in 17 patients with ischemic cardiomyopathy. 
The overall sensitivity and specificity of 
18
F-FDG PET to demonstrate functional recovery 
after surgery was 95% and 80%, respectively.  A meta-analysis summarizing 24 studies has 
reported a weighted sensitivity and specificity of 92% and 63%, respectively, with a positive 
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and negative predictive value of 74% and 87%, respectively, for the diagnosis of hibernating 
myocardium and prediction of patient outcomes. 
36
 Our results are consistent with these 
findings as the diagnostic accuracy of 
18
F-FDG PET compares well with other established 
techniques SPECT and echocardiography for viability assessment. 
18
F-FDG PET was found 
to have the highest diagnostic sensitivity when compared to SPECT and echocardiography in 
the assessment of myocardial viability.
 44
 
Despite these promising results, the use of 
18
FDG PET in the assessment of left ventricular 
dyssynchrony is dependent on the severity of CAD. Wang et al 
44
 in their recent study 
consisting of 100 CAD patients indicated that 
18
FDG PET should be carefully used in 
assessing LV dyssnchrony in patients with severe LV dysfunction. 
37-39 
In contrast, 
Pazhenkottil et al 
45
 reported an excellent agreement between SPECT 
99m
Tc tetrofosmin and 
8
FDG PET in the LV dysfunctional assessment,
 40-46
 and this is again in line with our reports. 
There are some limitations in this study that need to be acknowledged. First, the sample size 
is too small. This is either due to the number of patients who refused to participate in the 
study or due to the disease severity of CAD or unstable condition, which they decided to 
undergo revascularization treatment. Second, only patients with known or proven CAD were 
included in this study, thus, our results should be interpreted with caution. Lastly, assessment 
of myocardial contour cannot be eliminated completely, thus further investigation on how to 
delineate the myocardial boundaries more accurately are needed.
 45
 
In conclusion, 
18
F-FDG PET has high diagnostic value in the assessment of myocardial 
viability in patients with known CAD when compared to SPECT and echocardiography. 
Further studies based on a large cohort are needed to enable a robust conclusion to be drawn. 
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Chapter 6 Conclusions and Future Directions  
 
6.1 Conclusions 
 
In this thesis, diagnostic value of nuclear cardiology techniques, cardiac SPECT and PET was 
investigated when compared to invasive coronary angiography for detection of coronary 
artery disease (CAD). This research project was conducted at several stages consisting of 
retrospective analysis of cardiac SPECT in comparison with coronary calcium score; 
experiments on a realistic cardiac phantom to determine the imaging protocols, and 
prospective study of diagnostic value of cardiac PET in myocardial viability A systematic 
review of the current literature shows that PET has higher sensitivity, specificity and 
accuracy for detection of CAD than SPECT and PET/CT. PET can be used as a reliable, less 
invasive modality for functional analysis of patients suspected of CAD. 
 
A correlation of coronary calcium score (CAC) with myocardial perfusion (MPI) by SPECT 
in a group of patients with suspected CAD was performed.The study shows the limitations in 
using CAC scores alone as a predictor of coronary disease outcomes. Coronary calcium score 
should be combined with myocardial perfusion imaging in low-to-intermediate risk patients 
to improve the diagnostic performance. 
The cardiac phantom experiments showed the feasibility of demonstrating cold lesions 
created by the inserts in the left ventricle. This study provides opportunities of testing cardiac 
SPECT and PET with regard to optimization of imaging protocols in the evaluation of 
coronary artery disease. 
The prospective study comprising patients with known CAD shows that cardiac PET has high 
diagnostic sensitivity in the assessment of myocardial viability when compared to SPECT 
and echocardiography.  
The research outcomes are summarized as follows: 
 Cardiac PET is increasingly used in the diagnostic evaluation of coronary artery 
disease, and its diagnostic value is high compared to other less invasive imaging 
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modalities. This is confirmed by other systematic review and prospective data 
analysis. 
 Coronary calcium score is regarded as a highly sensitive marker of determining the 
atherosclerotic disease compared with conventional risk factors. However, in patients 
with a zero or low calcium scores, myocardial perfusion imaging demonstrates 
potential value of detecting abnormal changes.  
 Cardiac 18FDG PET has high diagnostic value in the assessment of myocardial 
viability in patients with proven coronary artery disease and it is recommended to be 
incorporated into clinical patient management with the aim of reducing cardiac 
events. 
 Both cardiac PET and cardiac SPECT need to be further validated based on phantom 
studies and clinical trials with regard to optimization of imaging protocols and 
reduction of radiation exposure associated with administration of 
radiopharmaceuticals. 
 
6.2 Future Directions 
 
This study improves our understanding of the diagnostic value of cardiac PET when 
compared to SPECT for detection of coronary artery disease.  However, there are few 
suggestions for the future research focus in following aspects: 
1) Although cardiac PET will continue to play a key role in the investigation of 
myocardial viability, more data are needed to confirm its clinical efficacy. 
 
2) Cardiac PET is not yet as widely available as SPECT imaging, thus, more experience 
is needed in image interpretation and operation as it may vary widely. 
 
3) Diagnostic accuracy of 18FDG PET could be variable from centres to centres, 
depending on the protocols used and level of confidence in interpretation. Therefore, 
optimization of PET imaging protocols is necessary. 
 
4) To investigate administration of radioisotopes/radiopharmaceuticals with the aim of 
reducing radiation dose associated with nuclear cardiology examinations. This is the 
area where little research has been conducted. 
